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ABSTRACT 
Transdermal drug delivery has recently received inaeasing attention in the face 
of growing challenges to deliver peptide and protein drugs. Controlled transdermal 
delivery is an important route for the delivery of peptides and proteins that can 
maintain the therapeutic effectiveness of the drug by minimizing enzymatic 
degradation which is a major concem in other noninvasive routes of delivery such 
as the oral route. Although the advantages of transdermal delivery are very 
desirable, the natural obstacle to drug entry imposed by the skin's barrier fundion 
makes it one of the most difficult route of administration. 
Iontophoresis and electroporation have been reported to be useful as permeation 
enhancing techniques in the transdermal delivery of protein and peptide drugs. The 
objedive of present study is to use the above enhancement techniques to deliver 
cyclosporin A (CSA) to treat psoriasis. 
The in vitro experiments were performed using hairless rat skin as the model with 
Franz diffusion cells for iontophoresis and custom made diffusion cells for 
electroporation. The donor drug solution of CSA consisted of an aqueous solution 
of CSA - polymer solid dispersion, coevaporate, and/or a hydroethanolic solution 
of CSA PBS was used as the receiver solution. 3H labelled CSA and 14C labelled 
ethanol were used to facilitate analysis using a liquid scintillation counter. The 
control experiment consisted of passive diffusion study. Silver/silver chloride 
II 
electrodes were used in all studies. In the iontophoresis experiments a constant 
DC current (0.5 mA/crn2) was used. In the electroporation experiments different 
delivery parameters were studied: (1) applied electrode voltage (U ..... ), (2) decay 
time ccnstant { T ), (3) the number of pulses delivered - single or multiple, and { 4) the 
time of diffusive contact with drug after electroporation ('contact duration'). 
Compared to the passive diffusion, iontophoresis did not result in a significant 
increase in the amount of CSA delivered transdermally with both the CSA-polymer 
donor and hydroethanolic drug solutions. 
With the use of electroporation there was a significant increase in the 
transdermal delivery, compared to passive transport. With the CSA-polymer 
coevaporate donor solution the increase in delivery was only about 6 fold higher 
whereas with the hydroethanolic solution the increase was about 60 times higher 
compared to passive diffusion. The 'contact duration• was an important fader and 
a 4-hour •contact duration• was found to be the optimum time period required for 
effective transdermal delivery. Use of single pulse ('t=5.6 ms) electroporation 
resulted in a significant increase {p<0.05) in the delivery of CSA in skin {CSA.n) 
and EtOH in receiver (EtCH...,). With multiple pulse ('t=10 ms. 25 pulses) the 
increase in CSA.n was more pronounced with a 60 fold increase than compared 
to the passive delivery. HC7N8ver there was no significant increase in the other two 
quantities viz. CSA..c.., and EtCH,.... 
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I INTRODUCTION 
1. 0 Transdermal Drug Delivery System 
Transdermal drug delivery has recently received increasing attention in the face 
of growing challenges to the delivery of peptide and protein drugs. Controlled 
transdermal delivery is an important route. which could maintain the therapeutic 
effectiveness of peptide and protein drugs and reduce their side effeds. As a non-
invasive method of delivery. transdermal delivery minimizes the risk of 
contamination and infedion associated with needle penetration. The therapeutic 
value of many drugs could be enhanced by transdermal delivery due to the 
elimination of gastrointestinal (GI) irritation, avoidance of the drug's deactivation 
caused by hepatic "first-pass" effect or degradation in Gl tract and reduction of the 
frequency of dosing for the drugs with short half lives. Transdermal delivery can 
also enhance absorption of the drug if a poor bioavailability is caused by the effect 
of Gl pH, enzymatic degradation in Gl trad or the drug interadions with food. Since 
peptide and protein drugs usually have very short half lives and poor absorption in 
the Gl tract, the delivery of them through the intad skin is aHradive and worth 
pursuing. 
In transdermal drug delivery, the drug molecules pass from the surface of the 
skin through its various layers into the systemic circulation. In conventional topical 
dosage forms, such as ointments and creams, the percutaneous absorption is 
1 
controlled by the skin membrane and the amount of drug delivered is unpredictable 
and uncontrollable. Significant progress has been made, in the last two decades, 
in achieving a better control in the delivery through the skin. The first transderrnal 
therapeutic system designed to control the delivery of drug to the skin for 
absorption was developed in 1980 by Alza Corporation, in which scopolamine was 
delivered for systemic absorption to control nausea and vomiting associated with 
motion sickness. Since then, a number of transdermal delivery systems have been 
developed and commercialized (Table 1 ). 
Although the advantages of transdermal delivery make this route of delivering 
very desirable, only a selected number of drugs are suitable as candidates for 
transdermal delivery due to the natural obstacle to drug entry imposed by the skin's 
barrier function. Research in transdermal delivery has been directed to find ways 
and means of delivering different types of drug molecules with the use of 
enhancement techniques to overcome the skin's barrier function. 
2 
Table 1 Examples of Transdermal Drug Delivery Systems • 
Therapeutic Type of System Trade Name and Manufacture 
agents 
Clonidine Four-layered Patch Catapres-TTS(Boehringer lngelheim) 
Estradiol Four-layered Patch Estraderm (CIBA) 
Fentanyl Four-layered Patch Duragesic (Janssen) 
Nicotine Multi-layered Patch Habitrol (Ciba-Geigy) 
Multi-layered Patch Nicoderm (Marion Merrell Dow) 
Multi-layered Patch Nicotrol (Wamer-Lambert) 
Multi-layered Patch Prostep (lederfe) 
Nitroglycerin Matrix Plastic Deponit (Schwarz Pharma) 
Polymer Adhesive Minitran (3M Pharmaceuticals) 
Polymer Adhesive Nitrodisc (Searle) 
Gel-like Matrix Nitro-Our (Key Pharmaceutical) 
Four-layered Patch Transderm-Nitro (Summit) 
Scopolamine Four-layered Patch Transderm Seep (CIBA) 
• Ansel HC et al. 1995 
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1.1 Skin Barrier Function Mel Percutaneous Absorption 
The skin is an integumentary system, which plays a major role in maintaining 
homeostasis, preventing the ross of body fluids and retarding the entrance of 
potentially toxic agents from the environment rather than being just an inert body 
wrapping.. It probably haS the lowest water permeability of any biologically 
prodiiC8d mernl:nl•. In serving as a banier, the skin also impedes the invasion 
of most microorganisms and protects the underlying tissue tram many external 
physical stresses. such as ultraviolet radiation, electrical energy anct mechanical 
fcrces. The strucb.n d the skin consists of three distinct layers, epidatmis, dermis 
and subcutaneous tissue, from surface downward (Figure 1 ). 
VEil --__...;~~r.:::--. I)W!\15 
ARTERY ---'~ 
SEBACEOUS GLAND ,.,_,.,.,~ft:fU 
----
WAIR FOLLICLE 
SWPT &LAND---~ 
PAPILLA OF' HAIR l~R~tfi!lfipjJ!lJ 
Figure 1 Structure of the Skin 
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The epidermis is a continually renewing stratified, squamous and cornifying 
epithelium layer. The majority of cells in the epidermis are the keratinocytes that 
keratinize and give rise to derivative strudure -appendages including sweat glands 
and hair follides. The epidermis varies in thickness from 0.04 to 1.5 mm, compared 
to 1.5 to 4 mm for the full thickness of the skin (Moschella SL eta/, 1992). 
One of the principal functions of epidermis is comification, a specific form of 
cellular differentiation that results in the formation of a highly resistant cutaneous 
barrier, which possesses the properties of physical toughness, high electrical 
impedance and physicochemical barrier to water and other foreign substances. In 
the process of cornification, epidermal keratinocytes undergo charaderistic 
changes, which is vertically oriented. At the end of this process, comified cells are 
arranged regularly and form orderly columns, a stacking of cells that varies 
somewhat on different sites of the skin. Within the comified layers, a type of fibrous 
protein, termed a-keratin. is formed and embedded in a sulfur-rich amorphous 
matrix. As the keratinocytes mature to comified cells, plasma membranes in the 
upper portion of epidermis become thickened by deposits of a thick band of protein 
on the inner surface of the plasma membrane, which is cross-linked by disulfide 
bonds and transglutaminase-dependent isopeptide linkages. The thickened 
cornified layer, about 15 nm thick, is named stratum corneum (SC). The SC ads 
as the main barrier for the entry of extemal agents through the skin (Moschella SL 
5 
et a/, 1992). The layer of the SC is composed of lipid-depleted comeocytes 
embedded in a complex mixture of polar and non-polar, lipid-enriched bilayer matrix 
in the intercellular space, presenting in the form of multiple lamellae (Jackson SM 
eta/., 1993; Wertz PW, 1992). The epidermal barrier is mediated by a series of 
intercellular multiple lamellae in the SC, which consist of cholesterol, ceramides (N-
acylsphingosines) and fatty acids (Schurer NY eta/, 1991 a). The barrier fundion 
of SC to permeation is attributed not only to the interstitial lipid composition but also 
to its unique arrangement as ordered multilayers (Potts RO eta/, 1991 ). The cells 
of SC in the epidermis of some mammalian species are precisely stacked in 
columns in a honeycomb fashion and architedurally organized parallel to the 
surface of the SC (Honda H et at .• 1996). The architecture of the SC was modeled 
as a "brick and mortar" structure, a two-compartment model, the protein contained 
in comeocytes as 'brick" embedded in the neutral bilayer lipid "mortar'' (Elias PM, 
1983; Barry BW, 1987; Wertz PW eta/., 1989). The more recent findings relate the 
skin's remarkable barrier property to the heterogeneous morphology of the SC, in 
which the SC is catabolically active and the intercellular domains are not a purely 
lipid compartment but possess considerable heterogeneity, i.e., a mixture of lipids, 
enzymes and membrane glycoconjugates and perhaps other constituents as well, 
consisting of both hydrophilic and hydrophobic lamellae (Elias PM, 1991 ). The 
heterogeneous morphological arrangement makes the SC more complicated in 
6 
permeation than a normal diffusion model (Heisig M eta/., 1996). 
The chemical insolubility and stability of SC derive from the presence of 
numerous disulfide and other highly resistant covalent bonds in proteinaceous 
envelope and intercellular neutral lipid strudures. The lipids include ceramides, 
free fatly acids, cholesterol and cholesteryl sulfate that are required for permeability 
barrier homeostasis (Mao-Qiang M et at., 1996). The chemical and enzymatic 
resistance and cohesiveness of SC are largely attributed to these protein and lipid 
envelope (Wertz PW et al .. 1989; Elias PM eta/, 1991; Schurer NY et al .. 1991 a; 
b). 
The dermis consists mostly of relatively ~llular connective tissue constituted 
of collagen, elastic fibers and ground substances, within which are embedded 
nerves. blood vessels, lymph vessels. muscles and follicle-sebaceous-apocrine and 
ecaine units. The dermis is 15-40 times thicker than epidermis, depending on the 
anatomic site (Moschella SL eta/, 1992). 
The subcutaneous tissue is technically not considered as part of the skin. It is 
primarily composed of connective tissue to attach the skin to the underlying organs 
and contains numerous fat cells to insulate against cold and store energy in the 
form of calories, rich network of blood vessels to regulate skin temperature and the 
complex system of nerves to register sensation. 
The skin is regarded essentially as an impermeable membrane. The 
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permeability of the skin shows regional variation and changes with aging probably 
because of the variation and change of lipid content and composition in SC (Lampe 
MA et a/., 1983; Ghadially R eta/., 1995). 
There is a molecular size constraint on penetration through the SC. The 
penetration deaeases dramatically as molecular size of the penetrating agent rises 
above 800-1000 Da (Wester RC eta/, 1985). 
The permeability barrier of the skin mainly resides in the epidermis and almost 
exclusively in the intercellular spaces of SC {Monash s. 1957; Elias PM eta/., 1977; 
Madison KC eta/., 1987; Elias PM, 1991; Potts RO eta/, 1992; Craane-van 
Hinsberg WHM et a/., 1995). The lipid content and lipid type in the SC determine 
the epidennal permeability banier. A relationship was found between the total lipid 
content of SC and Hs barrier function {Grubauer G eta/., 1989). The SC is a rate-
limiting membrane for passage of water, electrolytes and other substances between 
the extemal and internal environment of the body. 
There are two anatomic routes available for percutaneous absorption through 
intact skin (Figure 2): transcellular route and intercellular route. Recent studies 
indicate that skin appendages, hair follicles and sweat duds, act essentially as 
diffusion shunts in normal skin (Elias PM, 1991 ), which is a hydrophilic porous 
transport pathway and a relatively easy pathway through the skin for certain 
compounds, such as small ions. However, for most drug compounds. the 
a 
percutaneous absorption takes place across intercellular lipid multilayer domains 
of SC (Krill SL eta/., 1992a), which occupies a much greater surface area than the 
Intercellular Route Transcellular Route 
Epidermis 
Dennis 
Subcutaneous Tissue 
Figure 2 Percutaneous Absorption Through Intact Skin 
appendageal diffusion shunts. For peptides, both intercellular and shunts seem to 
be important in penetration (Craane-van Hinsberg WHM eta/., 1995). Two parallel 
penetration mechanisms are believed to be involved in the percutaneous 
absorption: partitioning through lipid pathway, and diffusion through hydrophilic 
pore pathway (Morimoto Yet a/., 1992: Sznitowska M eta/., 1995a; b). This 
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suggests that the percutaneous absorption of a compound will be largely 
determined by its physicochemical properties. The shunt route may fundion as 
diffusional route and bypass the low diffusivity domain of SC. However, the 
appendages provide a small portion of skin surface area, approximately 0.1% of 
total area of the skin (Scheuplein 11. 1967). It is unlikely that an appreciable number 
of continuous hydrophilic pathways exist in the SC considering the high electrical 
resistance of the skin (Oh eta/., 1993). Thus, enhancing drug penetration through 
the intact SC seems to be very important in achieving a successfu: transderrnal 
delivery. 
In abnormal skin, the permeability barrier of the SC could be changed. In 
psoriatic epidermis, for example, the defective permeability barrier function resulted 
in an increased transepidennal water loss (TEWL). which could be correlated to the 
severity of the disease (Ghadially R eta/., 1996). 
Between epidermis and dermis is the dermoepidermal jundion. a highly 
specialized attachment, which regulates the permeability across the interface 
between epidermis and dermis. The permeability characteristic of this layer is 
reported to depend on molecular charge of the penetrating species but not on their 
size. For a neutral or lipophilic compound, the thick dermis may offer a significant 
resistance to its permeation (Roy SO eta/., 1994). 
Besides the barrier function of SC. the metabolic capacity of the skin is also 
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considered as a barrier for percutaneous absorption during transdermal drug 
delivery (Martin RJ eta/., 1987). Both phase I and phase II readions occur in the 
skin, particularly in the epidermis. Many penetrating molecules may be metabolized 
in the epidermis by certain xenobiotic metabolizing enzymes, protease and 
esterase, which are known to be present in the outer layer of the epidermis (Menon 
GK eta/., 1986; Noonam PK eta/, 1985; Potts RD eta/., 1989). 
In certain disease state, for example in psoriatic skin lesions, the metabolic 
activity of enzymes may be subject to change that may induce changes in the 
xenobiotic substrate metabolism and endogenous substrate metabolism (Goerz G 
et at, 1992). 
1.2 Electrically Enhanced Permeation 
The permeability of skin can be increased by some chemical and physical 
means. The chemical enhancers have long been used in topical formulations. The 
effects of physical means are also being extensively investigated, such as 
increasing the permeability by use of heat energy (Krill SL et a/., 1992a; Prausnitz 
MR, 1996a) and use of ultrasound ( Ueda H eta/., 1995; Mitragotri S et a/., 1995; 
1996; Johnson ME et al., 1996). To deliver peptide and protein drugs, electrical 
enhancement techniques, to improve the permeability of skin, have been studied 
in the recent years. The most extensively investigated physical means of 
11 
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enhancing transdermal delivery is iontophoresis (Srinivasan V et al .• 1989;. Theip 
U et al .• 1991; Green PG et al .• 1993; Gangarosa LP et al .• 1995). Another physical 
means recanUy introduced in the field of transdermal drug delivery is the use of 
electroporation (Bommannan DB et at .• 1994; Prausnitz MR et al., 1993; 1995a). 
Both iontophoresis and electropcraticn involve the use of electrical energy and are 
separately discussed below. 
1.2.1 Iontophoresis 
Iontophoresis is a non-invasive technique which uses a low electric current. ~ 0.5 
rnNcrn2 (Prausnitz MR. 1996a). to facilitate the transdermal delivery of a variety of 
drugs. This technique has been in use for a long time and references dating back 
to the late 19th century can be found. 
In principle, iontophoresis is very similar to electrophoresis, in which charged 
partides migrate through a relatively stationary liquid phase under the influence of 
an applied electric field provided by immersed electrodes. In iontophoresis. the 
amount of electricity required to drive the molecules is much smaller than that in 
electrophoresis. The skin behaves as a drug transport barrier membrane between 
the two electrodes. The transport of charged species through the skin membrane 
depends on the magnitude of the applied electromotive force. the physicochemical 
nature of the species and the medium. Stratum comeum has been shown to be 
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negatively charged at physiological pH (Bumette RR et a/, 1987). This property 
facilitates the transport of cations in anodal delivery and is also coupled with the 
effect of electro-osmosis. For neutral species, electro-osmosis might affect the 
transport, in which electrically induced convective solvent flow acts as a driving 
force (Srinivasan V et a/, 1989; 1990; Wearley et a/, 1990). According to the 
Stokes-Einstein equation, 
lc Boltzmann constant 
T: absolute temperature 
n: viscosity 
r: radius of permeant 
(i-1) 
diffusivity of molecules. D is inversely proportional to the molecular size of the 
permeant (Peck KD et al., 1996). For the negatively charged agents with high 
molecular size, SC is almost a formidable barrier in passive diffusion because of 
the high lipophilicity of SC itself (Blank HI et a/, 1969). However, by suitably 
adjusting the composition of the donor and receiver solutions, electro-osmosis can 
be increased and also used to deliver the negatively charged species (Santi P et 
a/, 1996). 
The hydration of skin is reported to enhance iontophoretic delivery. Skin 
hydration is a reversible process and it is due to disorganization of the lipid layers 
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of the SC that leads to increased SC permeability (Jadoul A et al., 1996). 
Besides enhancing transdermal drug delivery, iontophoretic drug delivery may 
also be programmed to achieve controlled drug release from a drug reservoir to 
further improve drug therapy and patient compliance. In comparison with passive 
transdennal drug delivery, which is usually limited to deliver small, non-polar or 
lipophilic species, iontophoresis can deliver both ionic and non-ionic molecules 
including those with high molecular weight (Phipps JB eta/., 1989; Singh P et al, 
1994). To date, iontophoresis offers a feasible non-invasive alternative for the 
delivery of some polypeptide and protein drugs {Srinivasan V eta/., 1989; Singh P 
et at, 1994; Thyman S et at., 1994; Chen LLH et at. 1996; Green PG, 1996; Brand 
RM et at, 1996). 
1.2.2 Electroporation 
In electroporation, an exponential decaying high eledric voltage is pulsed for a 
very short duration of time {micro or milliseconds) to bring in transient changes in 
cell membranes or lipid bilayers (Piiquett U et at., 1996). The early studies of 
electroporation dates back to 1960s. It has been widely used in many different 
fields for different purposes, including gene transfer in mammalian cells, genetic 
manipulation in plant cells, genetic transformation of baderia and yeast, 
electroinjection of exogenous molecules for studying cellular functions and 
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eledroinsertion of protein and DNA into cell membrane (Chang DC et at, 1992a). 
The recent development in its application are in the field of transdermal drug 
delivery (Prausnitz MR eta/., 1993; 1994; 1995a; b; Vanbever R et at., 1994; 1996; 
Bommannan DB et at., 1994; Edwards DA et at., 1995; Riviere JR et at., 1995; 
Pliquett U eta/, 1996) and electrochemotherapy to deliver anticancer drugs to 
improve solid tumor chemotherapy (Mir LM et at., 1991; 1995; Belehradek J. Jr. S 
et al., 1991; Belehradek M et al., 1993; HeUer R et at., 1995; 1996; Glass LF eta/., 
1996). The use of electrochemotherapy in human subjeds testifies the clinical 
safety of this technology. 
When applied to lipid bilayers, it is hypothesized to destabilize the membrane 
lipids leading to the formation of transient intercellular pores (Chang DC eta/., 
1992; lnada H et a/., 1993; Orlowski S et a/, 1993; Bommannan DB et a/., 1994; 
Freeman SA eta/., 1994; Edwards DA et at., 1995; Prausnitz MR et at., 1995a). 
The mechanisms of tissue electroporation are complicated and most of the present 
hypotheses are scientific speculations. The formation of aqueous pores is believed 
mainly to be a biophysical process induced by electromagnetic field and can be 
charaderized by a reversible electrical breakdown of the membrane (Powell KT. et 
a/, 1986; 1989; Barnett A et at, 1991; Weaver JC, 1993, 1995). Under an external 
eledric field, the relatively high potential drop across the membrane is built 
because of the high electrical impedance of lipid bilayer membrane. Once the 
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electric potential drop across the membrane is higher than a certain threshold 
potential, the resting potential, a rapid process of structural rearrangement within 
the membrane occurs and results in a large increase in transmembrane 
conductance and molecular transport through temporarily formed hydrophilic porous 
membrane openings (Orlowski S eta/, 1993). The number and size of pores can 
be increased With the increase of pulse length and voltage of the applied pulses 
(Glaser RW eta/., 1988; Weaver JC, 1993). As pores form, the condudivity of the 
membrane is inaeased. The induced high conductance state in the membrane can 
limit the transmembrane voltage and therefore protect it. Similar to lipid bilayer 
membranes of cells, cell layers, such as SC of the skin can also be temporarily 
altered by the eledroporation (Chizmadzhev eta/., 1995). When applied on skin, 
the electric pulses create transient pores in the SC, which may facilitate drug 
transport Pliquett eta/. studied the effect of voltage and number of electroporation 
pulses on epidermis. They have reported that highly localized transport regions 
were formed in the epidermis with the use of high voltage electrical pulses. The 
increase in the applied voltage increased the number of regions with increased 
permeability and increase in the number of pulses increased the size of regions 
(Piiquett UF eta/., 1996). The efficiency of transdermal drug transport as well as 
the extent of changes in the skin are both dependent on the transmembrane voltage 
and the duration of pulsing. By optimizing the electrical parameters in experiment, 
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the pores created in SC could temporarily increase its permeability to deliver drug 
molecules, thereby ensuring that no long term damage is done to the protective 
property of the skin. lnaeased pore pathway in the SC could lead to increased skin 
permeability and prolong the post-pulse diffusion phase. The main driving forces 
in drug transport process are electrophoresis (or iontophoresis) and electro-
osmosis (Dimitrov OS et at. 1990; Weaver JC, 1993; 1995; Prausnitz MR et a/., 
1995a). 
1.3 Topical Delivery of Cyclosporin A for the Treatment of Psoriasis 
1.3.1 Psoriasis 
Psoriasis is a skin disease that is characterized by marked increases in 
keratinocyte proliferation, abnormal pattems of keratinocyte differentiation and 
prominent alterations in dermal capillary vasculature and presence of dermal and 
epidermal T cells, manocyteslmacrophages and neutrophils (Das UN eta/., 1992). 
It has a chronic relapsing nature and variable clinical features. The involvement of 
the skin could be small, isolated and localized region or generalized on the whole 
body. The morphology of the skin lesions of psoriasis varies considerably and is 
classified as scaly erythrosquamous that indicates the involvement of both the 
vasculature (erythema) and epidermis (increased scale formation). Epidermal 
keratinocytes display marked proliferative activation and differentiation (Fitzpatrick 
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TB et al., 1993). 
The occurrence of psoriasis is universal, ranging from 0.5% to 3% (Krueger GG 
et al. 1994). It diminishes the quality of life for a large number of people by causing 
not only economic loss but also human sufferings. including disability. discomfort 
and disfigurement (Krueger GG. 1993). 
Although the pathogenesis and etiology of psoriasis are not fully understood, two 
important mechanisms have been proposed: epidermal proliferation and an 
inflammatory/repair process (Krueger GG, 1989). It is reported to involve the 
immune system and has a genetic disposition (Gottlieb AB, 1988; Suarez-Aimazor 
MEet a/, 1990; Chang EY, 1992; Breathnach SM. 1993). The disequilibrium of 
certain major histocompatible antigens can be found with the disease expression. 
Since interleukin-2 (IL-2) therapy for malignancy in patients with a history of 
psoriasis induces severe psoriatic exacerbation, it proves that T cell-derived 
cytokines are inducers for psoriatic epidermal changes (Lee RE et al.. 1988). 
Besides the action of IL-2, the overexpression of interleukin-1 (IL-1) and tumor 
necrosis factor (TNF-a) in psoriatic epidermis, a high level of IL-6 expressed in 
psoriatic skin and an increase in the level of IL-8 derived from a variety of cells 
involved in the psoriatic reactions indicate the complexity of the cytokine network 
in psoriasis (Elder JT et a/., 1989; Romero Ll et a/., 1989; Christopher& E et a/ .• 
1989; Grossman RM eta/., 1989; Das UN eta/., 1992). All these facts demonstrate 
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the participation of the immune system in the etiology and pathogenesis of 
psoriasis. Moreover, the observation that psoriasis and Reiter's Syndrome (an 
autoimmune disease) may co-occur and be flared by infection with the human 
immunodeficiency virus (HIV), which dysregulates and destroys the human immune 
system, supports the hypothesis that psoriasis is an immunologically mediated 
disease (Madeleine 0, 1990). All these malfunctions of immune system in the 
psoriatic plaque is believed to occur in the viable epidermis and the jundion 
between epidermis and dermis of the skin (Valdimarsson H eta/., 1986; Wong RL 
et a/., 1993). 
1.3.2 Methods Currently Used in the Treatment of Psoriasis 
Various forms of treatment of psoriasis have been developed in the past several 
decades. The topical corticosteroid creams and ointments remain the most 
common first-line choice for the management of psoriasis. With the use of potent, 
fluorinated preparation, such as fluclorolone ointment, the incidence of side effeds 
has dramatically increased (Menter A et a/., 1991 ). The intralesional injedion of 
corticosteroids and other drugs is used to treat small, localized plaques. The total 
amount of the given drug and the depth of injection must be well controlled to avoid 
systemic side-effeds. 
Ultraviolet phototherapy at 311 nm wavelength is useful in treating psoriasis, 
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particularly in the treatment of superficial types of psoriasis. The photochemo-
therapy (PWA). using systemic psorialens plus ultraviolet light to treat psoriasis, 
was introduced in 1974 ( Panish JAeta/., 1974). Since then, the effediveness of 
PUVA in clearing psoriasis has been confirmed by many clinical studies both in 
United States and in Europe (Melski J et a/., 19n; Henseler T et al.. 1981 ). 
However, the side effeds and the consequences of overdosage have limited its 
usage. The long-term side effeds in skin damage are of considerable importance 
which makes it necessary to restrid PWA to patients with widespread and severe 
psoriasis. The PUVA freckles may persist for years and involve the risk for the 
development of skin cancer. Studies have confirmed that the treatment of psoriasis 
with PWA could inaease the risk of developing skin cancer (Mali-Gerrite MG et al .• 
1991; Chuang TV eta/., 1992; Studniborg HM eta/, 1993; Van-Praag MC eta/., 
1993; Stem RS et al. 1994 ). 
In the systemic treatment. use of corticosteroids is still the first-line choice. 
Improvement of symptoms can be obtained by the use of systemic corticosteroids, 
especially in the widespread and more acute forms of psoriasis. The mechanism 
is thought to be "anti-inflammatory" in the broadest sense. The major drawback is 
that a transient relief is often followed by a severe relapse of the disease and it 
almost always becomes more severe than before. 
Methotrexate (MTX) was used as an antipsoriatic agent for the systemic therapy. 
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It is known to inhibit DNA synthesis by competing as a substrate for dihydrofolate 
reductase and is thought to act primarily on the rapidly dividing epidermal cells 
within psoriatic lesions. It directly affects the proliferation cells. either epidermal 
keratinocytes or lymphoid tissue cells, by inhibiting cell cycle and by decreasing 
mitosis resulting in cell death (Weinstein GO et a/1990). However, topical use of 
MTX to psoriatic lesions is not effective (Weinstein GO et al, 1976). Systemic use 
of MTX is often accompanied by severe side effects that may lead to liver damage 
and cirrhosis. Fibrosis of the liver is seen in approximately 1 0 percent of patients 
treated for long period, and cirrhosis is seen in 5 percent (Zacharias H eta/., 1980). 
The cumulative dose of MTX has important impact on the risk of hepatotoxicity. For 
these reasons. MTX is only used in severe and recalcitrant psoriasis. 
Retinoids, derivatives of vitamin A. have been used as a treatment for psoriasis. 
The response to therapy is variable and depends on the type of psoriasis. The best 
outcomes have been in the treatment of pustular psoriasis or guttate psoriasis of 
recent onset (Ellis CN eta/, 1987). Retinoids are lipophilic and accumulate in the 
fat tissue after prolonged therapy. Pharmacokinetic studies revealed that after 
cessation of therapy, retinoids administered for psoriasis could still be detected in 
the plasma even 4 months after the last dose. Since retinoids have been proved 
to be teratogenic in several animal studies, they are contraindicated in female 
patients in their reproductive period of life (Windhorst DB eta/, 1982). 
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The combination of several therapies has also been applied to optimize the 
efficacy and to reduce the toxicity of individual drug treatments (Menter A et a/., 
1991 ). The treatment of psoriasis is far from perfect. The quest for a more potent 
and selective drug and more efficient clinical use of existing drugs are in progress. 
1.3.3 The Use of Cyclosporin A in Psoriasis 
Treating psoriasis with cyclosporin A (CSA) is thought to be a promising 
development. It appears to have more potential for treating psoriasis than any 
other therapy {Mahrle G eta/., 1995). Studies have shown over 90% of psoriatic 
lesion cleared after treating with CSA (Ellis CN eta/., 1986; Menter A et at., 1991 ). 
In fact, the clinical effectiveness of CSA has been considered a major advancement 
in the understanding and treatment of psoriasis. 
As a novel and effective immunosuppressant, CSA is a main component of 
metabolites isolated from the fungus, Tolypoctadium inflatum Gams. It has been 
used in the prevention and treatment of transplant organ rejection and autoimmune 
diseases in humans, since its immunosuppressive properties were found in late 
197rJs (Borel JF eta/., 1976a; b; c; Caine RY et at.. 1978; Powels RL et at., 1980). 
Because of its effective inhibition of the antibody and cell-mediated immune 
responses, CSA is used as an immunosuppressant which has improved the survival 
of patients receiving a variety of organ allotransplantation (Colonna JO eta/., 1988; 
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Borel JF et at., 1989a; 1991; Yamada S et at., 1994; Thiel G et at .. 1994). 
Mueller and Hermann (1979) first reported improvement in psoriatic plaques with 
the use of CSA Thereafter, many studies have confirmed that CSA is an effective 
agent in the treatment of psoriasis, including erythodermic, pustular and chronic 
plaques (Ellis CN et al .• 1986; Bos JD, 1988; Talal N, 1988; Heule F eta/., 1988; 
Griffiths CE et a/., 1989; 1990; Fradin MS et al.. 1990; Mainardi MM et a/1990; 
Farber EM eta/, 1993; Lewis HN, 1994; Laburte C et al., 1994). 
The pharmacology of CSA has been extensively investigated (Borel JF et at., 
1989b ). Its powerful selective immunosuppressive adivity is elucidated as the 
inhibition of both antibody and cell-mediated immunity, especially of lymphokine 
production secreted by activated T cells (Borel JF eta/., 1989b; 1990). In contrast 
to classical immunosuppressants, CSA specifically and reversibly ads on the 
lymphocytes and does not affect the function of phagocytes or hemopoietic stem 
cells. It affects the early steps immediately following antigen or mitogen 
recognition, which results in restriding the T -cells to remain in the resting phase of 
the cell cycle. The restricted T -cells are unable to transform and release 
lymphokines and thus fail to induce an immune response. CSA can also suppress 
an ongoing immune reaction or an autoimmune relapse. With reversible action, 
CSA does not cause lymphocytotoxic or mutagenic changes in the body (Borel JF, 
1989b). 
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In the treatment of psoriasis, CSA has been reported to inhibit several adivation 
pathways related to immune system (Bos JD, 1988). It is also postulated that most 
of the immunosuppressive effects of CSA are due to the inhibition of gene 
expression resulting in the inhibition of the produdion of IL-2 and of other 
keratinocyte cytokines (Gottlieb ABet at., 1992; Won YH eta/., 1994). Specific 
inhibition of T -cell infiltration and lymphokine secretion, keratinocyte proliferation 
and cytokine produdion as well as antigen presentation and cytokine secretion are 
believed to be involved as well (Valdimarsson H et a/., 1986; Shuster S, 1988; 
Dipadova FE, 1989; Ryfrel B, 1989; Griffiths CE eta/, 1990; Wong RL eta/., 1993). 
The formulations of CSA are marketed by Sandoz Pharmaceuticals Inc. and are 
available as intravenous formulations, oral solution (Sandimmune• ) and oral soft 
gelatin capsule (Vee GC, 1991 ). The oral absorption of CSA from Sandimmune• 
is slow and incomplete. Peak concentration in patients was reported to occur 1 to 
8 hours after oral dosing. Considerable inter-patient variations have been observed 
in the peak concentration of CSA. Clinical Pharmacokinetic studies revealed that 
the absorption phase of CSA was the rate-limiting step (Ptachcinski RJ et at., 1986; 
Fahr A. 1993). In this step, intestinal enzymatic degradation of CSA is substantial 
(Wu CY et at., 1995). 
Many studies have focused on the improvement of systemic absorption and 
bioavailability of CSA. Attempts were made by taking advantage of techniques of 
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enteric solid dispersion (Takada T et at., 1989), microemulsion (Tarr BD eta/., 
1989; Ritschel WA et al .• 1990; Mueller EA eta/., 1994; Trull AK et at., 1994; Ferea 
G eta/., 1994; Friman S and Bachman. 1996). by means of water-soluble vitamin 
E (Sokol RJ eta/., 1991 ), oral administration in an olive oil solution (Ueda CT eta/., 
1983; Takada K eta/., 1988), solid micellar solution (Crewe J et a/., 1992), 
liposomal formulation (Vadiei K eta/., 1989; Amoux R eta/., 1990; Stuhne-Sekalec 
L et at .. 1986a; 1986b; 1989; 1991; Freise CE et al .. 1991) and microsphere 
technique (Sanchez A et at., 1995). A new oral soft gelatin CSA capsules (Neora~. 
Sandimmune, Sandoz) has recently been introduced (Jewkes FME, 1995; Nobel S 
eta/., 1995), which incorporates the drug in microemulsion formulation containing 
surfactant&. The microemulsion formulation dose not depend on the bile salts for 
solubilization in the Gl trad and is claimed to have an improved bioavailability 
profile compared to Sandimmune•. 
CSA improves the skin of patients with psoriasis by a local mechanism of adion, 
in the epidermis and the jundion of epidermis and dermis (Ho VC et a/., 1990; 
Griffiths CE eta/, 1990; Bums MK eta/., 1992; Wong RL. 1993). The Inhibition of 
mitotic activity of CSA in psoriatic lesions to reduce hyper proliferation of epidermal 
keratinocytes suggests that, systemically administered, CSA could be first taken up 
preferentially by the lower layers of epidermis and then distributed upward with 
time. After oral administration, human epidermis contained a high concentration of 
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CSA The epidermis of psoriasis patients contained 10 times more CSA than the 
blood samples after 7 -day oral treatment with 14 mglkg/day of CSA (Fisher GJ et 
a/., 1988). Although no correlation between patient's clinical response and blood 
level of CSA was observed, a significant difference between the CSA uptake by 
psoriatic epidermis and non-psoriatic epidermis was found. Furthermore. CSA 
therapy did not impair normal epidermal fundions (Fisher GJ et a/., 1988). 
However, the systemic use of CSA can be accompanied by severe dose-dependent 
toxicities that include nephrotoxicity, hypertension and hepatotoxicity (Curtis JJ et 
a/., 1988; Mason J eta/., 1989; Griffiths CE eta/., 1990). The major toxicity of CSA 
is impairment of renal fundion, which has a high incidence in recipients with renal 
transplantation and patients with autoimmune diseases (van Graffenried B et a/, 
1986; Feutren G et a/., 1990). Infection and liver malfundion can also occur in 
these patients. High doses of CSA are toxic to cardiac myocytes in certain strain 
of mice and rats (Paul LC eta/., 1991 ), and probably in man as well (Oyer DE eta/., 
1983). CSA-induced neurotoxicity has also been reported (Pace MT eta/., 1995). 
These findings suggest a potential feasibility of using CSA topically in the treatment 
of psoriasis. 
In the treatment of psoriasis, the therapeutic efficiency of CSA with systemic 
administration is dose-dependent (Borel JF, 1990). The narrow therapeutic window 
of CSA (Shaw LM eta/., 1987; Holt OW eta/., 1991; Awni WM, 1992; Kivisto KT., 
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1992) combined with the erratic absorption and nonlinearity in the dose versus 
blood concentration relationship in oral formulation (Reymond JP et at., 1988; 
Mueller EA eta/., 1994) impose a risk of over- or under-dosing that may lead to 
inconsistencies in the treatment of psoriasis. Another shortcoming in the systemic 
use of CSA is its low bioavailability. The absolute bioavailability was estimated to 
be about 30°A. • ranging from 1 0% to 60% (Fahr A. 1993). CSA is the most 
expensive therapy in the treatment of psoriasis due to the relatively higher cost of 
medication and the laboratory tests to monitor renal status (Sander HM et a/., 
1993). In contrast, topical use of CSA is expeded to require a low dose which 
would avoid the systemic side effeds and would also cost less. 
CSA is extensively metabolized by the cytochrome P-450 3A enzyme family, 
which is a catalyst for the oxygen-dependent metabolisms and the major 
cyclosporine-metabolizing enzyme family located in both liver and small intestine 
in humans (Kronbach T et a/., 1988; Watkins PB, 1990; Shet MS et a/., 1993; 
Christians U eta/, 1993). Systemic delivery always leads to first-pass effect in the 
liver and/or in the gut wall of small intestine (Kolars J et al., 1991 ; Ducharme MP et 
a/., 1993; Lindberg FA eta/., 1994). About 1% unchanged CSA is excreted renally 
after systemic administration (Shah AK et al., 1995). Cytochrome P450 enzymes 
are ubiquitously distributed in the whole body. Besides liver, drug metabolic activity 
involving cytochrome P450 enzymes has been shown in kidney, lung and small 
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intestine (Gonzalez FJ, 1992). Although human lung and kidney contain P450 3A 
enzymes, no significant metabolism of CSA has been reported in these organs. 
CSA l.l1dergoes both phase I and phase II metabolisms. To date there are more 
than 30 CSA metabolites isolated from bile and urine of different species and from 
samples obtained after incubation of CSA with liver microsomes (Christians U eta/, 
1993). The sulfate conjugates are formed directly from CSA (Christians U eta/, 
1993). All these metabolites of CSA maintain their cyclic undecapeptide backbone 
structure intad. 
The skin is an active site of metabolic adivity. Metabolites generated in 
cutaneous tissue may diffuse to the bloodstream where they may move to extra-
cutaneous tissue and exert effeds therein. The epidermis possesses additional 
subcellular constituents that in general diminish the toxicity of xenobiotics, and one 
of them is the family of cytochrome P450 enzymes (Mukhtar H eta/, 1989). 
Although the epidennal P450 metabolizes a number of endogenous and exogenous 
compounds (Takahara H eta/., 1993; Jugert FK. 1994), CSAwas reported not to 
be metabolized in normal and psoriatic epidermis {Duell E et a/., 1991 ). The 
probable reason might be attributed to the IOYI content (about 5%) of P450 enzymes 
in epidermis. These fads suggest that topical delivery of CSA couiC. bypass both 
hepatic and gut metabolisms. Thus an effedive topical formulation of CSA that is 
able to penetrate SC will exert antipsoriatic therapeutic action at the required site. 
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without any noticeable systemic side effeds (Brown MD eta/., 1989; Fradin MS et 
at., 1990). 
Intensive search for an effective topical preparation of CSA for the treatment of 
psoriasis has been tried by different researchers. Although certain putative 
penetration enhancers have been used to improve skin permeability and absorption 
of CSA, such as olive oil, propylene glycol and Azon•. none has been able to 
deliver sufficient amount of CSA (Gilhar G eta/., 1988; Hermann RC et at .• 1988; 
Fradin MS eta/., 1990; Bunse T et at .• 1990; De-Ria MA eta/., 1991; Korstanje MJ, 
1992; Mrowietz U, 1992; Duncan Jl eta/., 1993). Liposomal formulation of CSA is 
also under in vitro evaluation (Egbaria K eta/., 1991 ). 
lntralesional injection has also been used in order to deliver CSA (Barker BS et 
at., 1989; Ho VC eta/., 1990; Bums MK et at .• 1992). The efficacy of intralesional 
CSA in the treatment of psoriasis, without any significant systemic absorption, 
indicated that CSA does not act solely through systemic route and that it has a local 
mechanism of action. Thus the several unsuccessful attempts to treat psoriasis 
with topical use of CSA may be due to inadequate penetration in the skin. However, 
the disadvantages with intralesional injection are that it is extremely painful to 
patients and that it is only applicable in the case of localized plaques (Ho VC et al., 
1990; Bums MK eta/., 1992). 
A transdermal delivery system that would result in a suitable concentration of 
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CSA in the skin without the invasive pain and risk of systemic toxicities would be 
very desirable. The main hurdles in achieving the required topical concentration 
of CSA are the barrier fundion of the skin and the physicochemical properties of 
CSA 
1.3.4 Physicochemical Properties of CSA 
CSA is a neutral, hydrophobic cyclic undecapeptide, with a molecular weight 
1203 Da (C82H111N110 12). The molecular structure of CSA is cyclo-[-(4-(E)-but-2-
enyi-N,4-dimethyi-L-threonyi]-L-homoalanyi-(N..methylglycyi)-(N-methyi-L-Ieucyi)-L-
valyi-.(N-methyi-L-Ieucyi)-L..alanyi-D-alanyi-(N-methyi-L-Ieucyi)-(N-methyi-L-Ieucyi)-
(N-methyi-L-valyl)-] (Figure 3). Ten of the amino acids are known and in position 
"1" is an amino acid, (4R)-4-((E)-2-butenyl]-4-methyi-L-threonine {MeBmt), which 
was never seen before (ROegger A et at., 1976; Petcher TJ eta/., 1976). NMR 
analysis of the molecule revealed a fairly rigid backbone and fixed combinations for 
the side chains except the amino acids in the position 1 and 2 {Loosile HR eta/., 
1985). All amino acids are natural L-amino acids with s.cantiguration except for the 
0-AJa in position 8 with R-configuration. Seven of the amino acid residues are N-
methylated (position 1 , 3, 4, 6, 9, 1 0 and 11 ). The successful total synthesis of 
CSA was first reported by Wenger RM (1984 ). 
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Figure 3 Molecular Structure of CSA 
In addition to CSA, the fungus. Tolypoc/adium inflatum, produces a number of 
metabolites with similar structures. They have been isolated and chemically 
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characterized {Borel JF eta/., 1991 ). These cycfosporins are all composed of 11 
amino acids and with only minor changes in amino acid units. Some of them are 
biologically inadive. None of the natural cyclosporins or synthetic analogous 
possess greater pharmacological potency than CSA in either in vitro or in vivo tests. 
Only a few of natural cydosporins, namely cyclosporin A, C, D, G and M, have been 
found to be effedive in in vivo. The unusual strudure of MeBmt in the CSA cycle 
structure seems to be involved biological effeds of CSA but alone it does not have 
any immunosuppressive adivity. 
All metabolites of CSA resulting from the in vivo biotransformation found so far 
have always maintained their cyclic peptide strudure intad. The majority of 
metabolites of CSA have been found to be less effedive than CSA itself {Radeke 
HH et a/.,1992) and do not contribute to the immunosuppressive effects of CSA 
(Freed BM et al., 1987; Garraffo R. 1992). Toxicity studies have shown that 
metabolites of CSA have less nephrotoxic potential and cannot account for the 
CSA-induced nephrotoxicity (Ryffel B eta/., 1988). 
The important physicochemical properties of CSA are summarized in Table 2. 
The behavior of solubility of CSA is unique. It was found to be inversely 
proportional to temperature (ranging from 5-37°C), and an exothermic heat of 
solution was indicated. Same solubility behavior had been found in aqueous 
solution with different pH values (lsmailos G, 1989). 
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CSA will lose its immunosuppressive activity if its cyclic strudure is destroyed. 
It was reported that acylating the hydroxyl groups of CSA results in significantly 
reduced activity (Wenger RM, 1989). Thus, changing structure by means of 
chemical approach to alter its physicochemical properties favorable for drug 
delivery may not be a useful strategy. 
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Table 2 The Physicochemical Properties of CSA * 
Cyclosporin A neutral, hydrophobic peptide 
Molecular Weight 1202.64 
Density 1.042 g 
Appearance white prismatic crystals 
Melting range 148-151 oc (natural) 
149-150°C (synthetic) 
log Poet 2.92-* 
logP• 1.40-* 
Solubility 
insoluble in water and n-hexane; very soluble in all other 
organic solvents, such as methanol, ethanol, ether and chloroform 
uv 
• Hassen MMA eta/., 1987 
.. Tayar NE et al., 1993 
end absorption at 200 nm 
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II STATEMENT OF RESEARCH PROBLEM 
The immunosuppressive peptide drug. CSA is dinically effective in the treatment 
of psoriasis. Systemic administration of CSA is fraught with the risk of severe 
side effects. Treating psoriasis topically with CSA would be desirable but no 
such delivery system Is presently available. 
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Ill RESEARCH OBJECTIVE 
SC is the main barrier in the skin for the tiansdermal drug delivery. Data derived 
trom morphological, histochemical and biochemical studies provide strong evidence 
that SC can be viewed as a heterogeneous two-compartment system of lipid-laden 
intercellular domain (Elias PM. 1991 ). To overcome the barrier function of SC and 
facilitate the drug delivery through it, electrically enhanced topical and transdermal 
drug delivery approaches, including iontophoresis and electroporation, have been 
used. These techniques are currently studied in our laboratory to enhance 
transdermal delivery of peptide drugs. 
The objective of present study is to develop a transdermal delivery system 
for CSA using iontophoresis and electroporation technologies. 
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IV RESEARCH HYPOTHESES 
In developing the research hypotheses, a brief background information is 
included as a prelude. The ability of drugs to penetrate human skin depends on 
several properties: skin strudure, lipophilicity and molecular size or configuration 
of the drug (Yoshida NH eta/., 1992). A number of unknown parameters related to 
these properties make it difficult to predid whether a particular molecule can be 
delivered transdermally. Several models have been developed to theoretically 
describe the transdermal transport of drugs {Guy RH eta/., 1989; Potts RO eta/., 
1989; Keister JC et a/., 1992; Edwards DA et a/., 1994). But they are too 
complicated to be used in pradice. For in vitro modeling of percutaneous 
absorption, Fick's first law of diffusion {ii) is still believed to be applicable in 
simplifying the analysis (Guy RH eta/., 1989; Sugibayashi K eta/., 1996). 
dQ DKpC 
- ( iv-1 ) 
eft h 
Equation (iv-1) is valid only in the sink condition, in which the rate of absorption 
of the drug by the skin (dQ/dt) is proportional to the concentration gradient or 
thermodynamic activity of the drug (C) across the skin membrane of thickness (h), 
and the partition coefficient of drug (K,J between skin and vehicle. D is the diffusion 
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coefficient. This indicates that the concentration gradient could be as a driving 
force in passive diffusion. Although more complicated models were proposed (Potts 
RO eta/., 1992; Kontturi K et at .• 1996), they give the same prediction in the trend 
to drug penetration using these parameters. To optimize diffusion, the 
thermoctynamic activity of the drug should be maximized without adversely affecting 
the partition coefficient of the drug. In order to effectively deliver CSA by 
iontophoresis and electroporation, the drug solution should not only have sufficient 
condudivity for the passage of electrical current but also have an optimum 
thermodynamic activity to facilitate diffusion. 
Water is considered as a universal solvent which constitutes 55-65% of human 
body weight. The state of hydration of SC is one of the most important faders in 
determining the rate of percutaneous absorption of a given solute. Hydrated SC 
has higher permeability for drug molecules. In this sense, water is very desirable 
as a vehicle for drug delivery through the skin. Water molecules exhibit a slight but 
physiologically important tendency of dissociation to act as either an acid or a base. 
which allows it to dissolve most physiologically important electrolytes and many 
drugs as well as to conduct electric current. Due to its ability to condud electric 
current. water is a good solvent for iontophoresis and electroporation. However. 
CSA is poorly soluble in water. 
Ethanol can destabilize the lipid phase of SC, leading to increased lipid chain 
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mobility (or fluidization) and/or lipid extradion (Krill SL eta/., 1992b; Ghanem AH 
et al., 1992). Ethanol has been extensively used in many topical preparations as 
a penetration enhancer. CSA is quite soluble in ethanol. Aqueous ethanolic 
solution of CSA has resulted in increased penetration in the skin (Egbaria K eta/., 
1990; l<im DO eta/., 1996). Its systemic toxicology and local tolerability have been 
well established. Ethanol, being a non-ionizable solvent, is a poor condudor of 
electric current and may not be a good choice for iontophoresis and eledroporation 
drug delivery. However, a hydroethanolic solution may combine the solvent 
properties of ethanol and water, and also provide the required conductivity. There 
is no report of using hydroethanolic solution as a solvent for iontophoresis and 
electroporation studies. 
Thus, the two problems in developing a transdermal delivery system for CSA 
using iontophoresis and electroporation are of thermodynamic activity of CSA and 
electrical condudivity of drug solution. This leads us to the following two 
hypotheses. 
Hypothesis 1: 
Solid dispersion (such as coevaporate) of CSA prepared with water soluble 
polymer will have increased aqueous dissolution, which will provide the 
necessary thermodynanic activity of CSA while maintaining a good electrical 
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conductivity. 
Hypothesis 2: 
Hydroethanolic solution will be a good solvent with a balanced solvent 
property for CSA without adversely affecting the electrical conductivity of the 
medium. 
Hypothesis 3: 
Electroporation and iontophoresis can be used as the permeation 
enhancement techniques to deliver CSA transdermally. 
The mechanisms of iontophoresis can be desaibed based on the modified 
Nemst-Piank flux equation (Keister JC et a/., 1992) 
aci z, F c. c3cl» 
J1= -D~--01 - :tJvCI(1-oi) 
~ RT ox 
J1: steady-state flux of the permeant i 
0 1: diffusion coefficient of the permeant i 
C1: concentration of the permeant i 
z,: charges of the permeant i 
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(iv-2) 
F: Faraday's constant 
R: gas constant 
T: absolute temperature 
$: electric potential at any point x in the membrane 
Jv= solvent velocity 
o,: permeanrs refledion coefficient 
at the membrane-solution boundary. 
In this equation the term ±JvCi(1- o1) is a measure of the transport of permeants 
resulting from the convective solvent flow or electro-osmosis. In a negatively 
charged membrane such as the skin, it facilitates the flux of positively charged 
perrneants and impedes that of negatively charged permeants. Therefore, the term 
+Jvc.<1- o1) can be used to account for the effed of convective solvent flow on the 
flux of positively charged perrneants, while the term -JvC1(1- q) can be used for 
negatively charged permeants (Srinivasan V eta/., 1990). 
Based on the modified Nemst-Piank equation (iv-2), drug permeation could take 
place in three ways: passive diffusion, electro-osmotic flow and electrical migration 
of ionic drug molecules. For non-ionic species, the eledro-osmotic flow ads as an 
additional driving force complimenting passive diffusion. For lipophilic compounds, 
transport of relatively small molecules is retarded through the hydrated pores in the 
skin (Dei-Terzo SO et al., 1989). For CSA which is a neutral, lipophilic molecule, 
iontophoretic delivery would mainly be due to the effect of eledro-osmosis. 
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Electroporation could involve three mechanisms to promote the molecular 
transport in transdermal delivery, which are electrical drift (electrophoresis, ion 
migration), electro-osmosis and passive diffusion (Dimitrov OS et al., 1990; 
Edwards DA et a/., 1994; Weaver JC, 1995)~ Besides electrical drift, the electro-
osmosis can enhance the penetration of both water-soluble and water-insoluble as 
well as neutral molecules. It is speculated to be important in the transport of 
macromolecules and neutral molecules in iontophoresis (Srinivasan V eta/., 1990; 
Pikal MJ, 1992). In electroporation, increased pore pathways and pore size may 
facilitate the effed of electro-osmosis and passive diffusional transport for neutral 
and lipophilic compounds, such as CSA 
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V MATERIALS AND METHODS 
5.0 Materials 
CSA and CSD were obtained from Sandoz Pharma Inc .• Switzerland and were 
used as received. [mebmt-P -3H-Iabeled] CSA was procured from Amersham Life 
Sciences, Ontario, Canada (specific activity: 6.00 CilmmoL; molecular weight: 1203 
at this specific activity; radioactive concentration: 1.0 mCilmL). Ethanoi-1-14C (14C-
Et0H) was obtained from Sigma•chemical Company, St. Louis, MO. USA 
(molecular weight 46.07. purity ~ 98%, specific activity: 8.1 mCi/mmoL, neat 
density: 0. 785) and made up to 50 tJCi/mL. Tritium water was obtained from Du 
Pont, NEN Products, Boston, MA. USA (specific activity: 37.0 mBqlgr or 1.0 mCi/gr, 
radioactive concentration: 1.00 mCilmL). The Cycle-Trac• SP-Whole Blood for the 
radioimmunoassay of CSA was obtained from lncstar Corporation (Stillwater, 
Minnesota, USA) 
Polyvinyl methyl ether maleic acid copolymer (Gantrezll S-97 BF. PVMEIMA) was 
obtained as a he sample from International Specialty Products Inc •• N J, USA and 
was used as received (molecular formula: -[C4H40 4-C3H80]-n; molecular weight: 
70,000). The tissue digesting solvent (Tissue and gel solubilizer, Solvable•. 0.5M 
solution) and scintillation cocktail (high flash-point LSC cocktail Formula-989) were 
obtained from Du Pont NEN Research Products, MA, USA. All other chemicals and 
reagents were of analytical or HPLC grade. 
43 
The HPLC system comprised a Hewlett-Packard pump system (HP-1050, 
Waldbroon, FRG), a multiple wavelength UV detector and an autosampler. A C18 
reverse phase column (Bondclone•, Phenomenex, CA. USA. 150 x 3.9 mm ) with 
a C18 guard column (4.60 x 3.9 mm) was used in the analysis of CSA. A liquid 
scintillation counter (Beckman LS 5000 TO, CA, USA) was used to measure 
radioactivity of radioisotope-labelled drug solution. 
Electrical power supply used for iontophoresis was PS 500 X DC Power Supply, 
Hoefer Scientific Instruments, San Francisco, LA USA. A custom made electronic 
circuit was used to maintain a constant eledric current in the in vitro experiments. 
Digital multimeters (Micronta•. lntertan Canada Ltd, Barrier, ON, Canada) were 
connected in circuit to monitor the voltage and current 
A Cell Porator8 (life Technologies Inc. ON, Canada) and a Gene Pulse,. II (Bio-
Rad laboratories, CA. USA) units were used respectively, as the source to generate 
single and multiple exponential electrical pulses in eledroporation. The eledrodes 
of Gene Pulse,e and BioRacf electroporation units were replaced with custom 
made Ag/AgCI electrodes. Wath the Cell Porato,.e an oscilloscope (Tektronix-, OR, 
USA) was attached to monitor the pulse waveform and measure pulse voltage and 
time constant The Gene Pulse,. unit had a built .. in panel where the pulse voltage 
and time constant were displayed. 
The Ag/AgCI electrodes used in both iontophoresis and electroporation were 
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made from silver wire (1.0 mm diameter, purity: 99.99 °At, Aldrich8 Chemical Co., 
WIS, USA). A layer of AgCI was deposited on the silver wire by immersing the 
silver wire in molten AgCI. The linear electrodes were used in iontophoresis with 
the lengths of 2 em in donor and of 7 em in receiver compartments. In 
electroporation, the silver wire was spiraled to form a circle with diameter of 0.5 em 
(area: - 0.2 cm2). 
Franz diffusion cells (Figure 4) were used in iontophoresis ( Laich•, industries 
Corp., USA). The iontophoresis electrical circuit is shown in Figure 4, in which a 
DC constant-current device used in circuit is a slight modification of the device 
reported by Su MH eta/ (1994). The output current is determined by measuring the 
voltage drop across a resistor (R = 1000 Ohms) with the Multimeter 1 (Figure 4). 
The current (mA) is equivalent to the voltage read from the Multimeter 1 divided by 
R (1000 Ohms). The Multimeter 2 is used to measure the voltage across the 
electrodes, a fradion of which is transdermal voltage (UIIdn). A stirring digital dry 
block heater (model274, PMC Dataplate•, Crown Bioscientific Inc., NJ, USA) was 
used to keep the receiver cells at 37°C. The effedive diffusional cross area of the 
skin samples was 0.80 cm2• 
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E I ( 0.4 rnA) R = 1000 Ohms 
DC Constant-Current ue~~CI 
~-----------·~--~------------------~ Multimeter 2 
~----------------~ 
Cathode 
~~,_.....,_. Donor Compartment 
Sampling ~====:;r=-~flr:..___ Skin Sample 
#----- Receiver Compartment 
-•-+------ Stirrer 
Figure 4 Schematic Diagram of Franz Cell and Iontophoresis Circuit 
Side-by-side diffusion cells (Figure 5), custom-made of Delrin (polymethanal. 
Dupont-). were used in electroporation experiments. The effective diffusion cross-
area of the cells was 1.3 cm2• The volume of both donor and receiver 
compartments were 0.8 mL. The distance between two electrode ports in the two 
compartments was 1 em. 
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-Receiver Compartment 
Donor Compartment 
lgure 5 Schematic Diagram of Side-by-Side Diffusion Cell 
and Electroporation Unit 
Model 925 pH meter {Accumet'>, Fisher Scientific. USA) equipped with gel-filled 
combination pH electrodes (Orion•. Orion Research Incorporated Laboratory 
Products Group, Boston, MA. USA) was used to measure pH values of all samples. 
Hairless rat (Harlan Sprague Dawley, IN, USA. 5-6 weeks old) was selected as 
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the animal, whose skin was used as model membrane in the transdermal delivery 
experiment of CSA Freshly excised skin was used within 48 hours in all the 
experiments. All fat and muscle tissues were carefully removed with surgical 
scissors and forceps. The skin was then kept soaked in PBS solution and hydrated 
for at least 1 hour before use. The integrity of the skin could be ascertained by the 
multimeter readings and any skin samples showing abnormally low electrical 
resistance was discarded. 
5.1 Analyses 
5.1.1 HPLC Analysis 
The concentrations of CSA from aqueous test samples were determined using 
an HPLC procedure described in the U.S.P. XXII [USP XXII, 1990] after modifying 
it to suit our laboratory conditions. The instrument was controlled and monitored 
using the ChemStation• software supplied by Hewlett Packard. The column was 
maintained at 70°C. The mobile phase consisted of 75% acetonitrile in water 
delivered isocratically at 1.5 mUmin. The UV detector was set at 210 nm to detect 
CSA in the sample. CSD was used as the intemal standard. Standard curves were 
obtained using standard solutions of CS~ ranging from 0.5 ~g/ml to 5 J,~g/mL. All 
samples were of 500 ~o~L to which 25 ~L of CSD (1 00 ~glml in mobile phase) was 
added. Twenty ~L of the solution was injected in duplicates. All measurements 
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were based on CSAICSD peak height ratio. Standard curves were prepared with 
each set of experimental test solutions. 
5.1.2 Liquid Scintillation Counting (LSC) 
The donor CSA solution was spiked with radiolabelled 3H-CSA to facilitate 
analysis. CSA concentrations in the skin. receiver and donor compartments before 
and after iontophoresis and electroporation experiments were determined by 
measuring the radioactivity of tritium from 3H-CSA using single label LSC program. 
The measurements were made in DPM (disintegrations per minute). The 2-sigma 
error was set at s 10% (maximum counting time = 20 min). The standard curves 
were prepared using the OPM of known strengths of CSA solutions which were 
prepared with each set of experimental test solutions. The background radioactivity 
was measured in each set of experiment using non-labelled samples and 
subtracted from samples' DPM values. 
In order to study the transport of water and ethanol across the skin, a donor 
solution containing 3H-H20 and14 C-EtOH was used. For this purpose the 
scintillation counter was programmed to dual label counting, with 2-sigma error set 
at s 5% (maximum counting time = 10 min). Other procedures used were the same 
as those in single label LSC. 
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5.1.3 Radioimmunoassay (RIA) 
Analysis of CSA by RIA was attempted to ascertain that the CSA in the skin 
detennined throughout the project using LSC was indeed the intad CSA molecules 
and not a fragment. Both skin and receiver samples were measured. Ethanolic 
solution containing 3.00 mglml of unlabeled CSA was used as donor solution. The 
RIA reagents supplied with the RIA kit of CYCLO-Trac• SP-Whole Blood were 
added to the samples as follows: 
(1) Total count tubes: 100 ~L of 1251-CYCLO-Trac SP 
(2) Nonspecific binding tubes: 50 IJL of extraded 0 standard, 1 00 IJL of 1251-
CYCLO-Trac SP, 1.0 ml of CYCIO-Trac SP NSB lmmunoSep 
(3) CYCLO-Trac SP 0 Standard: 50 ~L of extracted CYCLO-Trac SP 0 
Standard 100 IJL of 1251-CYCLO-Trac SP 
(4) CYCLO-Trac SP Standards (A-E): 50 IJL of extracted CYCLO-Trac SP 
Standard, 100 J,JL of 1251-CYCLO-Trac SP 
(5) Control and test samples: 50 IJL of extraded samples, 100 JJL of 
1251-CYCLO-Trac SP 
All tubes were incubated at 20-25°C for 1 hour, and then were centrifuged using 
1600 x g, where g = 1118 x 10"' (radius in an) (rpm)2, for 20 min at 20-25 oc. The 
supernatant from all the tubes was decanted except the total count tubes and the 
precipitate of each tube and total count tubes was counted using a gamma 
scintillation counter (LKB, Wallac OY, Turku, Finland ) for 2 min. All determinations 
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were in duplicate. The standard curve. %8180 (percent of specific binding to 
nonspecific binding) versus log concentration, was plotted using three cycle semi-
log graph paper. The amount of CSA in samples was detennined from the standard 
curve. 
5.2 Preparation of CSA-PVMEIMA Coevaporate 
5.2.1 Preparation 
CSA and PVMIMA copolymer in different weight proportions (w/w of CSA to 
PVMAIMA respedively 1 :5. 1 :8 and 1 :1 0) were weighed and dissolved separately 
in distilled ethanol. The two solutions were mixed and solvent was evaporated 
completely in a flash evaporator. which was set at 100 revolutions per minute (rpm) 
and soac. The coevaporates were further dried in a desiccator under vacuum, 
pulverized and sifted through a standard sieve (sieve NO. 70., pore size 2121Jm). 
5.2.2 Equilibrium Solubility of CSA from Coevaporate 
The equilibrium solubilities of the coevaporates and untreated CSA were 
detennined in deionized water at room temperature (22 :t 1 °C). For this an excess 
of the test sample in deionized water was shaken using an eledrical shaker. until 
the equilibrium solubility was reached (about 20 hours). The samples were then 
centrifuged, filtered through 0.45 ~o~m polyvinylidene fluoride filter (Millipore•. 
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Yonezawa. Japan) and analyzed by HPLC to determine the amount of CSA 
dissolved in water. The experiments were performed in duplicate or triplicates and 
the mean values were reported. 
5.2.3 Dissolution of CSA from Coevaporate 
Dissolution tests were done using a Vanderkamp R 600 [Vankel Industries Inc. 
NJ. USA] modified USP type 11. six-spindle dissolution apparatus. One litre of 
deionized water at 37°C was used as the dissolution medium. The stirrer was set 
at 50 rpm. Coevaporate powder sample, equivalent to 2.5 mg of CSA, was placed 
in a nylon bag and tied to the paddle. This was done to prevent withdrawing any 
solid particles during the sampling procedure. Aliquots of 1 ml aqueous samples 
for analysis were withdrawn periodically and centrifuged at 13200 rpm for 5 
minutes. To a 500 ~L portion of supernatant aqueous samples 25 IJL of CSD(1 00 
~o~g/ml) was added and mixed. Twenty JJL of the solution was injeded into HPLC 
column for quantitative analysis. The volume of the dissolution medium was 
maintained constant by replenishing the aliquot sample with fresh medium 
equilibrated to 37°C. Cumulative amount of CSA released at each time point was 
determined by averaging results from four determinations. 
Untreated CSA and the physical admixture of CSA and PVMIMA copolymer (1 :8) 
were used as controls. Since one of the factors contributing to poor dissolution 
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could be inadequate wetting, an experiment was done to determine the role of a 
Mtting agent in improving the aqueous dissolution of CSA. where 5 mg of CSA was 
mixed with 2 mg of a surfactant mixture of Span-80 and Tween-20 in a wlw ratio 7:3 
(HLB 8.0) and the mixture was used as the test sample for a dissolution test in 
water. 
5.3 Coevaporate Solution for Iontophoresis and Electroporation 
Based on the above dissolution studies, 1 :8 CSA/PVMAIMA copolymer was 
chosen for further studies. Labelled CSA eH-CSA) was incorporated during 
preparation of the coevaporate (0.056 JJCi/mg). The donor solution for the 
transdermal experiments consisted of CSA solution in isotonic phosphate buffered 
saline (PBS), in which the concentration of CSA was 64 JJg/mL (radioadivity of 
solution: 0.03 (JCi/ml, pH 7.0 - 7 .5). PBS was made of 138 mM NaCI, 8.1 mM 
Na2HP04, 2.7 mM KCI, and 1.1 mM 1<Ji1 PQ , and the pH was then adjusted to 
about 7 .4, using NaOH or HCI solution. The donor solution was freshly prepared 
and used within 48 hours. 
5.4 Ethanolic Solution of CSA for Iontophoresis and Electroporation 
The hydroethanolic donor solution for the transdennal experiments consisted of 
0.3°A. CSA (3.00 mg/ml) in 40 % ethanol (in PBS, v/v). Dual labelled solution viz. 
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~-CSA (0.1 05 JJCi/ml) and C1•-Et0H (0.05 ~o~Cilml) enabled analysis of both the 
drug and ethanol. The ethanolic donor solution was freshly prepared in each set 
of experiment. 
5.5 Control 
The control experiment comprised a passive diffusional transport study of CSA 
The composition of donor and receiver solutions and duration of experiments 
remained the same for both test and control experiment In the test experiment, 
iontophoretic current or electroporation pulses were used, while in the control 
experiment the drug transport was solely due to passive diffusional force. 
5.6 Iontophoresis 
Iontophoresis was conduded using Franz diffusion cells. The hydrated skin 
sample was sandwiched between the donor and receiver compartments with SC 
facing the donor compartment {Figure 4). The Ag/AgCI electrodes were used to 
conduct DC current passing the diffusion cell during iontophoresis. The anode 
(positive eledrode) was placed in donor compartment while cathode (negative 
electrode) in receiver compartment (Figure 4 ). The initial experimental runs 
resulted in a deposition of AgCI on the SC surface. Therefore, a piece of filter 
membrane (Millipore®, 1.2 IJm, Millipore Corporation, Bedford, MA. USA) was 
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placed on the surface of SC to prevent occlusion of SC surface from AgCI 
precipitate. The anodal electrode was inserted into donor compartment while the 
cathodal elecbcde was inserted into receiver compartment. A constant DC current 
was supplied by a DC power supply with an electric current 0.4 rnA. After 
subjecting the skin samples to 8 hours of iontophoresis, the experimental set up 
was allowed to stand for other 16 hours for passive diffusion. During the 
iontophoresis experiment, the receiver temperature was maintained at 37°C using 
a stirring digital dry block heater. The donor samples were taken before and after 
iontophoresis experiment. The receiver samples were taken before, during and 
after iontophoresis experiment. After iontophoresis experiment, the skin samples 
were taken out and the circumference of the skin which didn't contad the donor and 
receiver solution was trimmed off. The remaining skin (0.80 cm2) samples were 
washed with 3 x 1 ml of deionized water, to remove the adhering CSA from the 
surface of the skin. After air drying for 3~0 min, the skin samples were stripped 
1 0 times using Scotch• adhesive tape (3M, Ontario, Canada). At the end of the 
stripping process, the skin surface glistened which is an indication of removing all 
the layers of SC. Then the skin was completely digested in 1 ml of tissue digesting 
agent (Solvabletu) maintained at s~ooc for 3-5 hours. Thereafter to all the 
samples, 1 0 ml of scintillation cocktail (Formula-989) was thoroughly mixed to 
enable analysis of CSA with the liquid scintillation counter. The amount of CSA 
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was calculated based on the DPM measured after subtracting the background 
radioactivity. 
5. 7 Electroporation 
5. 7.1 Single and Multiple Pulse Electroporation Experiment 
Exponential pulses were used in the electroporation experiment. The 
experimental parameters that were studied are as follows: 
(1) applied electrode voltage (U....,.) 
(2) decay time constant of applied exponential pulse, 
or pulse length ( J) 
(3) contact duration of experiment 
( 4) number of pulses - single or multiple exponential pulses 
The applied electrode voltage, u ..... , is defined as the peak value of voltage 
of an exponentially decaying electric field applied between electrodes, anode 
(positive electrode) and cathode {negative electrode), in electroporation. The 
decay time constant or pulse length, 't. is the time required for the value of u..._. 
drop to 37 % of original. The contad duration is the period of time for which the 
donor drug solution is in contact with the skin during the experiment. 
Single pulse electroporation experiments were conducted at u..._., ranging 
from 100 to 370 V. Two pulse lengths. 5 and 10 milliseconds (ms), were tried. 
56 
The full-thickness hairless rat skin, including both from ventral and dorsal side, 
were used in the in vitro electroporation experiment The skin was cut to 
appropriate size and sandwiched between two custom made side-by-side diffusion 
cells (Figure 5), with the SC facing the donor compartment 
The donor solution used in this part of experiments was either 3H-CSA labelled 
CSAIPVMA-MA (1 :8) coevaporate aqueous solution or 3fi-CSA and 14C-EtOH dual -
labelled ethanolic solution of CSA The concentrations of CSA in both coevaporate 
aqueous solution and ethanolic solution were lower than their respective 
equilibrium solubilities of CSA so as to avoid precipitation of CSA. The receiver 
solution was PBS. The anodal electrode was placed in the donor compartment 
while the cathodal electrode in the receiver compartment All the experiments were 
performed at the room temperature (22±1 °C). 
The skin was allowed to equilibrate for one hour with PBS before initiating 
electroporation experiment After the electric pulses of known value of u.,._ and 
-r were delivered, the test unit of diffusion cell was left to stand undisturbed for a 
given contact duration. After experiment, the skin sample was dismantled from 
diffusion cell and washed with 1 ml of 40% ethanol and 3 x 1 ml deionized water. 
Thereafter, a skin sample was punched out using a biopsy punch (Area: 0.87 cm2) 
to quantify the amount of CSA delivered within the viable layers of the skin. As 
mentioned earlier under iontophoresis, the SC was stripped using adhesive tape 
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and the remaining skin was completely digested in tissue digesting agent 
(Solvable TM). 
Besides the skin samples. aliquot samples, 50 IJL from donor and 250 IJL from 
receiver, were taken before and after the experiments to measure the amount of 
CSA in the donor and receiver compartments. All digested skin samples, test 
solution samples and SC tape-stripping samples were analyzed with liquid 
scintillation counter. The analysis procedure was the same as that described in 
iontophoresis. 
In the multiple pulse mode, totally 25 pulses, at an interval of 1 min between 
pulses, were delivered. All samples were treated as same as that in single pulse 
experiment. u..... used in multiple pulse experiment was chosen as 200 V. 
Different pulse lengths, -r. from 0.9 to 10 ms, and contad duration, from 2 to 12 
hours, were chosen to study the optimum experimental conditions. 
To analyze samples with RIA, the skin samples were homogenized after the 
multiple eledroporation experiment at u ...... = 200 V, 't = 10 ms and contact 
duration = 4 hours. The homogenates were added to 4 ml of methanol to extract 
CSA for 24 hours. Then, extracts were centrifuged at 3000 rpm for 5 min. Two mL 
of supernatant of extracts was transferred to a volumetric flask and made up to 10 
ml with methanol. Aliquots of 0.4 mL of receiver sample were taken after 
electroporation, and evaporated with nitrogen flow at 30°C. The residues were 
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dissolved with 400 ~L of methanoL The samples were centrifuged at 3000 rpm for 
5 min before the use. The fresh skin was used as a control compared to the skin 
samples which YJere subject to the multiple electrcporation experiment The control 
for receiver samples was done using 40% ethanol (in PBS) as donor solution. 
5. 7.2 Solvent Transport Induced by Electroporation 
In this experiment. single and multiple eledroporation pulses were delivered at 
Ue~ec:~rac~e = 200 V. 't = 10 ms. The skin sample was allowed to equilibrate for 2 
hours to measure transport of solvents due to passive diffusion before subjeding 
it to electroporation pulses. Aliquots of receiver samples were drawn at periodic 
intervals up to 24 hours and analyzed. The donor solution was 40% ethanol in 
PBS. in which both water (0.1 05 1JCilml) and ethanol (0.053 JJCi/ml) were labelled. 
The samples were analyzed using scintillation counter to calculate the transport of 
water and ethanol. 
5.8 Electron Microscopy 
To observe any microscopic changes in the skin structure after electroporation, 
electron microscopic study was performed. The samples consisted of freshly 
excised and hydrated untreated skin and skin after eledroporation. Duplicate 
samples were prepared in each instance. The electroporation experimental set was 
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the same as that desaibed earlier (section 5. 7.1) with multiple pulse mode, u..__ 
= 200 V and J= 10 ms. Immediately after the electroporation, the skin was fiXed 
in glutaraldehyde fixative (0.1 M cacodylate buffer, pH 7.2). The skin samples were 
left overnight in the same fixative at 4 o C and were later washed repeatedly with 
0.1 M cacodylate buffer and post-fixed in 0.5% buffered ruthenium tetroxide (Ru04). 
containing 2% potassium ferrocyanide for 1 hour at 4°C. Then the skin samples 
YJere dehydrated in ethanol and embedded in Spurr's low-viscosity resin. Ultrathin 
sections of the skin samples were stained with uranyl acetate and lead citrate, and 
viewed under a transmission eledron microscope (Jeol, TEM-1200EX, Eledron 
Microscope, Toyota, Japan). 
5. 9 Statistical Analysis of Data 
All experiments have been done as multiple determinations and the x (mean) :t 
SO are reported. Non-parametric statistical methods were used to evaluate data. 
Analysis of variance and other statistical evaluations were done using Minitab8 
software (Minitab Inc .• PA, USA) with a level of significance: p = 0.05. 
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VI RESULTS AND DISCUSSION 
6.0 HPLC Analysis for CSA 
To demonstrate that the chemical integrity of CSA in coevaporate was retained, 
HPLC analysis of untreated CSA and coevaporate were performed. The HPLC 
chromatograms of the caevaporate were comparable with that of untreated CSA 
and there were no extra peaks (Figure 6). This indicated that CSA in the 
coevaporate had maintained its chemical integrity. The chromatogram exhibited 
well resolved peaks for CSA (retention time - 3.50 min} and CSD (retention time -
4.30 min). The peak resolution could be measured using: 
In our analysis, R. > 2.5. 
(t2-t1) Rs=----
0.5(fw,+fw2) 
R.: resolution of adjacent peaks 
~: retention time of the peak 
t_: peak width 
(vi-1) 
To measure CSA, standard curves produced on different days using stock 
solutions with different concentrations of CSA resulted in a statistically well 
correlated straight line (Figure 7). The regression equation for the standard curve 
was: 
Peak height ratio HCSNCSo = 0.025 + 0.26 CCSA (vi-2) 
R2 = 0.99, CV = 4.9 %, n = 5, linear range: 0.5 - 5 ~glmL 
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Figure 6 HPLC Chromatog,.ms 
Coevaporate VS Standard 
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6.1 Physicochemical Properties of Coevaporate 
6.1.1 Equilibrium Solubility of CSA from Coevaporate 
The equilibrium solubilities (at 22 :t 1 °C) of CSA from untreated samples and 
CSA from CSA-PVMEIMA copolymer are shown in Table 3. The CSA released from 
coevaporate had 7 to 9.5 times increased solubility as compared to untreated CSA 
samples. 
Table 3 Equilibrium Solubility of CSA (22 :t 1 °C) 
Samples Solubility of CSA 
J,Jg/ml ± SO (n=3) 
CSA (untreated) 9.25 :t 0.21 
1 :5 coevaporate 63.10 ±7.89 
1 :8 coevaporate 88.43 :1: 1.68 
1 :10 coevaporate 82.17 ± 3.18 
6.1.2 Dissolution of CSA from Coevaporate 
The CSA released from the coevaporate showed significantly improved aqueous 
dissolution profiles (Figure 8). The cumulative CSA released from the 
coevaporates 1:5. 1:8, and 1:10were. respedively, 82, 95 and 85%. To elucidate 
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the kinetics of drug released from the coevaporate, the percentage of CSA 
remaining to be released from the coevaporate as a function of time was fitted 
separately to the following equations: 
Zero order 
First order 
[ a. -Qt ] = a_ - Kot 
In ( [ a_ -1 = lnQ. - ~t 
(vi-3) 
(vi-4) 
In the above equation, parameters a_ and {l represent, respectively, the 
percentage of CSA released at infinite time and at any time, under the experimental 
conditions. Ko and 1<. are, respectively, the zero and first order rate constants. 
The correlation coefficients (R2) for the two equations were considered as the 
indicator for the order of release. For the three formulations 1 :5, 1 :8 and 1 :1 0, the 
values of R2 were, respectively, 0.95, 0.53, and 0.58 for the zero order fitting and 
0.96, 0.84, 0. 72 for the first order fitting. These results suggest that the release of 
CSA from the coevaporate could be considered following first order kinetics. 
As the percentage of the polymer in the coevaporates was increased from 83.3% 
(1 :5) to 88.9 % (1 :8), there was a significant increase (p < 0.05) in the cumulative 
amount of CSA released. However, regardless of further increasing the percentage 
of polymer in coevaporate to 90.9% (1 :1 0), the cumulative amount of CSA released 
did not inaease. Since the PVMEIMA is a water-soluble polymer, which can form 
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a viscous gel at a higher concentration, it is envisaged that the reduced cumulative 
release from 1 :10 coevaporate could be due to the increased diffusional barrier at 
the higher polymer concentration in the 1:10 coevaporate. The same trend was 
also observed in the equilibrium solubility studies of the coevaporate. 
The control experiments using untreated CSA. CSA-PVMEIMA admixture and 
CSA wetted with Span-80 and Tween-20 did not result in any improvement in the 
dissolution of CSA The amount of CSA released in all above instances was below 
the detection sensitivity of our HPLC analysis (0.5 IJg/ml). This demonstrated that 
the hydrophobicity of CSA could not be overcome by simply improving the wetting 
of CSA particles. The lack of dissolution of the physical admixture of CSA and 
PVMEIMA might suggest that the polymer itself has little or no direct effect in 
solubilizing CSA in water. It appears that CSA and PVMEIMA in the coevaporate 
are associated in a unique way, which is essential in improving the dissolution of 
CSA. The formation of molecular dispersion could be a possible mechanism for the 
improved dissolution of CSA The polymer, PVMEJMA, has a hydrophobic polyvinyl 
backbone and a maleic acid hydrophilic side chain. Therefore, the polymer can ad 
as an amphipathic molecule and facilitate the dissolution of hydrophobic drugs 
(Krishnan TR et at., 1991 ), such as CSA 
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6.2 Skin Model 
In the study of topical and transdermal drug delivery, the challenge of finding a 
suitable animal model whose skin attributes are similar to the human skin has been 
pursued by many investigators for several decades. Apparently, human skin is 
unique. There is no universally acceptable animal skin that could be 
interchangeably used for transdermal studies. Even for human skin. different skin 
types have different epidermal permeability barrier function although race and 
gender do not influence this function (Reed JT et at .• 1995). Since the availability 
of human skin is limited, using an animal model to conduct in vitro and in vivo 
experiments is unavoidable. In vitro experiments with different animal models have 
shown that permeability varies from species to species. Studies have also shown 
that permeability of the pig skin and guinea pig skin seems to be similar to that of 
man. particularly for the penetration of lipophilic compounds (Priborsky Jet a/., 
1990; Sate K et a/., 1991 ; Dick IP et a/., 1992). Hairless rat skin has been 
extensively used by many investigators. Using hairless skin avoids the need for 
shaving the skin that could cause accidental cuts leading to deceptive results. It 
was reported that hairless rat dorsal skin showed similar permeability to human 
breast and thigh skin (Harada K et at .. 1993). However. the different lipid content 
and water uptake lead to different skin permeability between human SC and that of 
hairless rat skin (Morimoto Y et at., 1992). It was reported that the permeability of 
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I ipophilic drugs in man is slightly higher than that in hairless rat. In the case of 
hydrophilic drugs, permeability has been reported much lower in hairless rat than 
in human (Morimoto Yet al., 1992). Despite all the differences animal models are 
useful in the development of the most suitable drug delivering conditions that could 
later be tried in human volunteers. 
The heterogeneous skin is composed of a comparatively lipophilic SC and a 
hydrophilic epidermis and dermis. Based on this fact, a parabolic relationship may 
be expected between lipophilicity of the drug and skin permeability {Hansch C et 
a/., 1973; Lee CK et a/., 1994). The high lipophilicity of CSA could be a 
disadvantage for its penetration through the skin, because drug molecules may tend 
to be trapped in the SC rather than penetrate into the relatively hydrophilic deeper 
skin layers. The successful development of CSA as a transdermal therapeutic 
agent will clearly be aided by an understanding of the influence of lipophilicity on 
the absorption of drugs across the skin barrier. 
Before conducting iontophoresis or electroporation, we had hydrated the skin for 
at least one hour. It was found that as the skin was hydrated the electric resistance 
across the skin declined and approached a stable value, which indicated the extent 
of hydration of the skin. The fully-hydrated skin is believed to be more permeable. 
The reason could be that water-hydrated skin has an increased fluidity in the 
intercellular membranes of SC, which could facilitate the water flux through the skin 
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(Alonso A eta/., 1995; 1996). The strudure of fully hydrated SC is reported to be 
swollen due to the uptake of water (van Hal DA et at., 1996). The existence of 
localized water domain in the intercellular region of the SC may shorten the 
diffusional path length through the lipid region of the SC for the hydrophilic 
molecules. On the other hand, a shorter diffusional path reduces diffusional 
resistance that may also facilitate the diffusion of lipophilic and amphiphilic 
molecules. 
The passive electrical properties of the skin are reported to exhibit a 
characteristic change with time after it was separated from the body (Piiquett F et 
a/., 1996). To avoid dramatic changes in the electrical properties in the skin 
samples, we have used all skin samples within 48 hours after excised from the 
body. 
6.3 Tape-Stripping Technique 
The tape-stripping technique has been used for a long time in transdermal 
research. This technique was initially used to study the rate of epidermal 
replacement (Pinkus H. 1952; Porter D et at., 1967; Downes AM et at., 1967). By 
using tape-stripping technique in transdermal drug delivery, we can obtain some 
insight into drug concentration profile within the SC (Tsai JC eta/., 1991 a). In the 
study of iontophoresis, this technique has been used to examine the role of the SC 
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in defining the electrical behavior of the skin (Ruddy SB et a/., 1995). In our 
experiments, tape-stripping technique was used as a means to remove SC 
selectively enable us to measure the amount of CSA delivered into the viable skin 
layers. By removing the SC before determining the amount of drug delivered 
transderrnally, we avoided any artifact effect caused by the drug adsorbed in the 
superficial layers of the skin. In all the results reported in the this thesis the 
measurements of transdermally delivered drug were done after removing the SC. 
With 10 consea.ative strippings, the counts of radioadivity in the tapes approached 
nearly constant, which suggested a complete removal of the SC from the skin. The 
quality of the adhesive tape was reported to have an influence on the stripping 
efficiency (Tsai JC eta/., 1991b). We used Scotch® (3M, Ontario, Canada) 
adhesive tape which gave satisfadory results. 
6.4 Non-parameter Statistics 
Skin samples are known to exhibit a wide variation in its electrical properties 
(Piiquett U eta/., 1995). Since the standard deviations in our results were high a 
normal distribution of data could not be assumed. Hence it was considered to use 
nonparametric statistical analysis of variance. Mann-Whitney test and Kruskal-
Wallis test were respectively performed for two and several sample populations. 
Pair-wise multiple comparisons were made using Mann-Whitney test after adjusting 
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fer Type I error. The amount of CSA in the skin (CSA.t,J. in the receiver (CSA..c.,.) 
and EtCH delivered into receiver (EtOH~KMw) and in the skin (EtOij.. ) are 
reported. 
6.5 In Vitto Iontophoresis 
In vitro iontophoresis was done using both coevaporate aqueous solution and 
hydroethanolic solution as donor solutions. The anode electrode was placed in the 
donor compartment, while the cathode electrode was placed in the receiver 
compartment to maximize electro-osmosis (Pikal MJ, 1992). It was reported that 
the maximum painless current for iontophoresis could be estimated using : 
28.6A 
/=---
48.3 +A 
(vi-3) 
where I is current (rnA) and A is electrical contact area (cm2) (Prausnitz MR, 
1996a). In our experiments, the current we used was 0.4 rnA that was lower than 
0.47 mA , the calculated value of perception threshold according to the equation vi-
3 {A = 0.8 cm2). 
With the use of Ag/AgCI electrodes and chloride-containing donor and receiver 
solutions, the electrolytic reaction can be represented as: 
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Cathode (vi-5) 
Anode (vi-6) 
Overall reaction: Ag + cr· ... AgCil + e· (vi-7) 
There are tYJO advantages in using Ag/AgCI electrodes. Firstly. the readion at the 
electrode does not cause a change in the pH in both donor and receiver solution 
because the process does not involve dissociation of water. Secondly, the readion 
at the electrode does not generate competing ions in the anode because the silver 
chloride produced during the reaction is virtually an insoluble salt (solubility 
produd: 1.25 • 1ct10 at 25°C, Martin A eta/., 1983), which precipitates at the 
electrodes. In most of the instances Ag/AgCI electrodes do not significantly 
contaminate the medium in which they are used. These tYJO benefits make Ag/AgCI 
electrodes suitable in iontophoresis (Sage BH Jr. et at., 1992). 
The results of iontophoresis were summarized in Table 4. The changes in pH 
values before and after experiments in both donor and receiver compartments were 
not large. either with the use of coevaporate donor solution or ethanolic donor 
solution. This suggested that the electrical property of the skin was not significantly 
altered, and that anodal delivery and the diredion of electro-osmosis were 
maintained during iontophoresis. 
Compared to control, the passive diffusion, the amount of CSA delivered into the 
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skin (CSA....)and receiver (CSA..c.v.,) by iontophoresis was not significant, either 
using coevaporate aqueous donor solution or ethanolic donor solution. Ethanol 
delivered to the receiver compartment (EtCH...-) by iontophoresis was not 
significantly different from that in the control. These results suggested that 
iontophoresis is not effective in transdermally delivering CSA which is a large, 
neutral lipophilic species. 
Although Ag/AgCI electrodes are approved for use in USA in iontophoretic 
devices (Sage BH, 1993), recently some concems have been expressed regarding 
its safety issue. Migration of ions from donor compartment to receiver compartment 
across the skin occurs when an electric current is applied. In the relatively long 
time of delivery, the toxicological aspects of migrating silver ions produced from the 
electrodes used in iontophoresis must be taken into account because the filter 
membrane we used may not thoroughly shield the skin from silver ions. Some of 
the recent findings suggest that movement of silver ions beyond the immediate area 
of eledrode placement is possible (Hollinger MA, 1996). Although silver ions are 
generally considered to be fixed by tissues due to binding with the protein at the 
site of application, an iontophoretic device can generate an electrical driving force 
to deliver silver ions across the tissues (Maloney JM et a/., 1992). This makes it 
possible for the free silver ions to penetrate the skin in depth. The free silver ions 
can interad with sulfhydryl, amino, imidazole, phosphate, or carboxyl groups in the 
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skin (Petering HG, 1976). The permeability of the skin may also be altered. 
Table 4 The Results of Iontophoresis 
Coevaporate 
~PHc~onor llpH,.._ CSA.,. 
x x x(ng)±SD 
Control 0.11 0.48 0.61 9:1:0.40 
Iontophoresis 0.20 0.51 0.606:1:0.49 
Mann-Whitney 
p 1.00 (NS) 
Hydroethanolic Solution 
~pHdonar ~pH..._ CSA... 
x x x(JJQ)±SD 
CSA..v.r 
x(IJQ)±SD 
CSA...v., 
x(ng):tSD 
0.013±0.00 
0.024±0.03 
0.84 (NS) 
EtOH..._ 
x(mg)±SD 
n 
5 
5 
n 
Control 0.30 0.57 0.039:t0.04 0.061:1:0.05 19.616±6.35 5 
Iontophoresis 0. 78 0.48 0.070±0.04 0.1 01:1:0.06 12.835:1:4.64 5 
Mann-Whitney 
p 
Control: Passive diffusion 
NS: Not significantly different 
Sig: Significantly different 
0.22 (NS) 0.31 (NS) 0.10 (NS) 
~pHdonor: The change in pH in the donor solution before and after experiment 
~HNC~Mr: The change in pH in the receiver solution before and after experiment 
75 
6.6 In Vitto Electroporation 
In electroporation experiments, the exponential decaying electric voltage was 
applied aaoss the skin sample through the side-by-side diffusion cell. The 
transdermal voltage (U .... ) of the skin directly affects the formation of transient 
pores in the SC. However, it is very difficult to measure it because it depends on 
a number of faders, such as electrode size, spacing. material and composition of 
the donor and receiver solutions as well as transdermal resistance (Ru..). which is 
highly time-dependent during electroporation (Piiquett U eta/., 1995). The local 
potential drops across the different media are different after pulsing and are 
relatively lower for donor and receiver solutions due to their higher conductivities. 
The skin has high local field strength because of its low electrical condudivity. 
Compared to other layers of the skin, SC has a significantly high local field strength 
due to its high lipid content. which leads to very low eledrical condudivity. Our 
electroporation units record only the voltage applied across the electrodes, u....,.... 
It is recognized that only a fradion of the u ... would appear across the skin 
(Piiquett U et a/., 1995). We did not have the experimental facility and the 
sophisticated electrical circuit required to determine the corresponding voltage 
across the skin, u ..... for each IJ•••=nc~e· Although not an ideal description, in this 
thesis reference will be made only to the u..._ which was recorded in an the 
experiments. The pulse length, 't, is determined by the combination of capacitance 
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(expressed in farads, F) and resistance (expressed in ohms, 0) in a circuil 
Capacitance depends on the capacitors in the circuit and resistance is largely 
determined by the sample, which in this case is the skin. Both u..._. and -r 
together can decide the waveform of applied exponential pulse. 
During the eledroporation pulse, the transmembrane voltage, U(t}, increases and 
the value depends on the type of membrane. Then, a reversible electrical 
breakdown (REB) occurs which is accompanied by increased molecular transport 
across the membrane. Although paradoxical, it seemes that at higher voltage there 
is a protective mechanism where the pores formed provide large condudance and 
prevent the U(t) from reaching very high values (Weaver JC, 1995). 
6.6.1 Induced Transport of Solvents During Electroporation 
The transport of water and ethanol under the effect of electroporation were 
measured to understand the mechanisms of electroporation. It is expected that 
transient pore pathways are created during electroporation, which can result in 
enhanced electro-osmosis and post-pulse diffusion. The results are summarized 
in Table 5. The results show that electroporation significantly increases the 
transport of water and ethanol with either single or multiple pulse modes. at 
u ...... = 200 V and'[= 10 ms. The transport of water and ethanol peaked about 
2 hours after single pulse electroporation (Figure 9) and after about one hour after 
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multiple pulse electroporation (Figure 1 0). The transport profile of ethanol was 
similar to that of water in both single and multiple pulse electroporation. It was 
noted that multiple pulse electroporation was more efficient in increasing the 
transport of the solvents than single pulse mode by a fador of 2 for water and 1.5 
for ethanol. Also the transport of water was 3 and 4 times higher than ethanol 
under single and multiple pulse electroporation, respectively. These observations 
seem to confirm the theory, in which creation of hydrophilic pores has been 
attributed as the possible reason for enhancement of aqueous solution transport 
aaoss the skin under the influence of electroporation (Prausnitz MR et al., 1995a; 
Pliquett U et al .• 1995). The higher transport of water could be attributed to the 
following reasons: (1) Water being more polar (1.84 Debey units) than ethanol (1.69 
Debey units) will be more influenced by the electrophoretic force. (2) Water has a 
smaller molecular size than ethanol and also has a higher molar concentration in 
40°la ethanolic donor solution. Hence. water will be better able to compete with 
ethanol for available pores to go through. It should be noted that despite having a 
smaller transportation rate, transport of ethanol is very significant since it is 
valuable for the delivery of compounds, such as CSA. that are insoluble in water but 
soluble in hydroethanolic solution. 
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Table 5 Tansport of Water and Ethanol Induced by Electroporation 
Single Pulsing 
Time ~0 Ethanol 
(hr) x :1: SO (mg/1.3cfn21hr) x :t SO {mg/1.3cm2/hr) n=5 
1 0.38 :1: 0.18 0.09:1:0.02 
2 1.25 :1: 0.48 0.32 :1: 0. 14 
2.5* 5.60 :1: 2.56 1.38 :1: 0.67 
3.5 5.47 :1:2.00 0.99 :1: 0.48 
5 8.17 :1:2.78 1.94 :1: 0.64 
7 6.57 :1: 1.46 1.55 :1: 0.32 
9 5.03 :1: 0.43 1.21 :1: 0.23 
24 3.71 :1:0.56 0.99 :1:0.16 
Multiple Pulsing 
1 0.55 :1: 0. 78 0.51 :1: 0.87 
2 1.41 .0.72 0.54.0.14 
2.5** 7.16 ± 1.70 1.54 :1: 0.52 
3** 13.44 :1: 5.27 2.29 :1: 1.10 
3.5 14.98 ±8.82 3.01 :1:1.89 
5 11.56 :1: 3.47 2.51 :1: 0.96 
7 8.90 :1: 1.63 2.19 :1: 0.58 
9 6.95 :1: 1.19 1. 73 :1: 0.24 
24 5.09:1:0.77 1.53 :1: 0.20 
• the time of applying electroporation pulse in single pulse mode 
** the time of starting and terminating electroporation pulses in 
multiple pulse mode 
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6.6.2 Delivery of CSA from Coevaporate Aqueous Solution 
CSA is virtually insoluble in water. Previous attempts by other investigators to 
deliver CSA topically without using physical methods of enhancement had met with 
only limited success (Gilhar G eta/., 1988; Hermann RC eta/., 1988; Fradin MS 
eta/., 1990; De-Rie MA eta/., 1991; Egbaria K eta/., 1991; Duncan Jl eta/., 1993; 
Choi HK eta/., 1995). The possible reasons for poor topical delivery of CSA could 
be due to its higher molecular weight, property of neutrality and the lack of a 
balanced olw partition coefficient. By using solid dispersion technique, we 
succeeded in increasing the aqueous solubility of CSA by a factor of 10. The 
dispersion or coevaporate consisted of CSA and PVMAIMA copolymer in a ratio of 
1 :8 (wlw). The concentration of CSA released from the coevaporate in donor 
solution was 64 ~o~glml of CSA, which is 7 times higher than its solubility in water. 
The higher thermodynamic adivity of coevaporate aqueous solution of CSA was 
expeded to facilitate the electroporative delivery of CSA. 
Experiments were done using both single and multiple pulse electroporation 
modes. The u.-.... used in both single and multiple modes were 150 and 200 V. 
The "C varied between 5 and 10 ms. 
The results of delivery of CSA from coevaporate aqueous solution by 
electroporation are shown in Table 6. The contact duration in all the experiments 
was 4 hours. Although the scintillation counter measured the radioadivities (DPM) 
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for the samples with very low drug content, it was not possible to differentiate 
between the CSA concentrations below the 10 ng level with enough accuracy. 
Hence, the CSA concentrations equivalent to or beiO\Y 10 ng are shown as < 10 ng 
in Table 6. 
Table 6 Delivery of CSA from Coevaporate Aqueous Solution 
Single and Multiple Pulse Modes 
the skin and in the receiver compartmenl However, with the use of electroporation 
there was a significant increase (p <0.05, Kruskai-Wallis test) in the amount of CSA 
delivered into the skin (CSA.aan)- Compared to the passive diffusion there was a 6 
to 8 fold increase in CSA..a,. with the use of single electroporation pulse at u......,. 
= 150 and 200 V (-r = 10 ms). 
With the use of multiple pulse mode at the two u.._._, 150 and 200 V ( -r = 1 0 
ms), a smaller accumulation of CSA was found to be in the skin, compared to that 
in single pulse eledroporation. The amount of CSA delivered into the receiver 
(CSA...t..) was lower than the limit of sensitivity of assays ( < 10 ng), similar to that 
in passive diffusion experiments. In the multiple pulse mode at u.._.. = 150 and 
200 V ( -r = 10 ms), detectable quantities of CSA (CSAr.c.. ) were also transported 
across the skin to the receiver compartment, significantly different from passive 
diffusion (p < 0.05 Kruskai-Wallis test). However, there was no significant 
difference in CSA...v. between Uelec:trode = 150 and 200 V (-r = 10 ms) in multiple 
pulse mode (p > 0.05, Mann-Whitney test). Also, increasing the -r from 5 to 10 ms 
in multiple pulse eledroporation at 200 V, CSA...v. did not show any significant 
difference (p > 0.05, Mann-Whitney test). 
The total amount of CSA delivered, which is the sum of CSA.aan and CSA...,, 
at 150 and 200 V ( -r = 10 ms) with single and multiple pulse mode was not 
significantly different (p > 0.05, Mann-Whitney test). The total amount of CSA 
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delivered at 200 V using multiple pulse mode with -c = 5 ms and r = 10 ms was 
also similar (p > 0.05. Mann-Whitney test). This is contrary to the literature reports 
where an increase in pulse length resulted in increased mass transport of other 
drug molecules through the cell membrane or skin (Zimmerman u. 1982; 1986; 
Pliquett U et al.. 1996 (a)). It is speculated that the lack of adequate 
thermodynamic activity of CSA in the donor compartment could be the main reason 
for not seeing any enhancement in CSA transport with increase in pulse length. 
After both single and multiple electroporation, pH did not significantly change in 
donor and receiver compartments. This indicated that electroporation did not 
involve any significant amount of ion migration between donor and receiver 
compartments in our experiments. 
The transient pores created in the skin during electroporation lead to increased 
diffusion of molecules from the donor compartment to the receiver compartment 
aaoss the skin banier. Since diffusion is a concentration dependent phenomenon. 
a seven fold increase in the ccncentration of CSA in the donor coevaporate solution 
may not be sufficient to maintain a satisfadorily high thermodynamic activity of CSA 
during the eledroporation experiments. 
By analyzing the strippings of SC. it was found that the amount of CSA in SC was 
40-50 times higher than that in the viable skin. This. however, may not be of any 
therapeutic value in treating psoriasis since the CSA in SC is not expected to 
85 
penetrate to the deeper part of the skin where it is required (faster desquamation 
occurs in psoriatic skin than in normal skin). It is recognized that although a 6 to 
8 fold increase in topical delivery of CSA compared to passive delivery was 
obtained with the use of electroporation, it is probably not a therapeutically 
significant quantity. One way to improve the delivery would be to increase the 
thermodynamic activity of CSA in the donor solution, which is discussed in the next 
section. 
After a contact duration of 4 hours, donor solutions were analyzed by HPLC. No 
extra peaks were found in chromatogram after electroporation. It may also be 
speculated that under the influence of electroporation, some amount of PVMEIMA 
could have been transported from the coevaporate solution in donor site to the skin. 
No attempt was made to quantify the amount of PVMEIMA transported during the 
electroporation. The amount of PVMEIMA contained in donor solution is not 
expected to cause any toxicity since PVMEIMA is considered a safe excipient (Urrtti 
A. 1985; Palomo F et at., 1989). 
6.6.3 Delivery of CSA from Ethanolic Donor Solution 
Delivering CSA from ethanolic donor solution by using electroporation as a 
means of skin permeability enhancement was encouraging. The CSA has a higher 
thermodynamic adivity in hydroethanolic solution (3% of CSA dissolved in 40% 
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ethanol and 60% PBS), in which the concentration of CSA is 3.00 mg/mL. The 
increase in solubility was significanUy higher compared to 64 IJg/mL in coevaporate 
aqueous solution and about 91JS)fml in water. The ionic strength provided by PBS 
also seemed sufficient to provide the required electrical conductivity for the donor 
solution. It is suitable for as a donor solution in electroporation. The pH values of 
the donor and receiver solutions were only slightly changed after electroporation 
experiments in both single and multiple pulsing modes. It ranged from 8.0-7.0 in 
the donor and 7.4-7.0 in the receiver solution. Maintenance of a neutral pH in the 
skin would ensure minimal irritation to the skin. 
It is reported that extemal electrical potential leads to deterioration of peptide 
drugs (Huang YY eta/., 1996). We analyzed both donor and receiver solutions 
after electroporation with HPLC to determine the integrity of CSA The CSA in 
receiver compartment was undetectable with HPLC. No extra peak was found in 
the HPLC chromatogram compared to that obtained with the CSA solution before 
subjecting it to electroporation pulses. 
Skin Variation Both dorsal and ventral parts of the hairless rat skin were used 
as skin samples. The radioactivity of the strippings on which the SC was lamellarly 
stripped showed a gradual decrease of radioactivity, which indicated the decrease 
of amount of CSA as the deeper layers of SC were reached. On comparing the 
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CSA..n, CSA...- and EtCH_._ between the dorsal and ventral side skin samples. 
no significant difference (p > 0.05} was seen (Table 7). In passive diffusion where 
the SC was not under any electrical influence, any regional variation in the skin if 
present would be expected to result in different amount of EtOH delivered. The 
data suggest that. in passive diffusion, regional variation in the barrier function of 
the skin has no influence in the transport of EtOH and CSA. 
Deterioration of barrier· property of the skin on short term storage of the excised 
skin was checked by comparing the CSA..an , CS~ and EtO~ between 
freshly excised skin and skin taken after 48 hours of storage at 0- 4°C. The 
variations in the transport of CSA and EtOH between freshly excised and stored 
skin were found to be insignificant (Table 8). An important feature of our in vitro 
experiments is the use of full-thickness skin rather than epidermis used by some of 
the other scientists (Bommannan DB eta/., 1994; Pliquett U et at .. 1996 (a)). 
Although it is acknowledged that SC is the main barrier in transdermal delivery, we 
believe that use of the whole skin would simulate the in vivo conditions more 
completely. 
Effect of Contact Duration of Study It was noticed that the contact duration 
had a varying effect in the efficiency of transderrnal delivery, which are summarized 
in Table 9. The three groups of experiments chosen for comparison were passive 
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diffusion, single pulse (U ...... = 200 V. -r = 10 ms). and multiple pulse 
electraporation (U.....- = 200 V. -r = 10 ms, 25 pulses/1 pulse per minute). Pair-
wise comparisons were made only between adjacent groups such as between 2 and 
4 hours, 4 and 6 hours contact duration etc. In the passive diffusion, although 
Kruskai-Wallis test showed both CSAr...v., and Et0f1.c.. were significantly 
different (p < 0.05). on performing pair-wise Mann-Whitney comparison only 
EtOH..,. was found to have significantly higher amount delivered when the 
contact duration was increased from 2 hours to 4 hours. The same observation was 
made earlier (see Table 7). 
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Table 7 Regional Variation of the Skin in Passive Diffusion 
Amount Ventral Skin Dorsal Skin p 
x :1: SO (n) x :t SO (n) 
Contact Duration = 2 hours 
CSAs,. (JJg) 0.256:t0.411 (7) 0.114±0.212 (9) 0.223(NS) 
CSA...w (JJg) 0.141:t0.148 (7) 0.200±0.235 (9) 0.791(NS) 
EtOH_._ (mg) 0.866±0.504 (7) 0.97 4:t0.304 (9) 0.751(NS) 
Contact Duration = 4 hours 
CSAs,. (~g) 0.412±0.175 (6) 0.570±0.394 (5) 0.4286(NS) 
CSA..c.v. ( IJg) 0.353±0.1 83 (6) 0.186±0.166 (5) 0.1775(NS) 
EtOH_..(mg) 2.126±0.806 (6) 2.018±0.852 (5) 0.5368(NS) 
p value: calculated using Mann-Whitney test. level of significance: 0.05 
Table 8 Effect of Storage of the Skin 
Amount Freshly Excised Skin 48-hour Stored Skin 
x :1: SO (n) x :t SO (n) 
CSA...,. (JJg) 1.42%1.55(3) 1.84:t2.58(3) 
CSA...w (JJg) 0.41 :t0.31 (3) 0.65±0.57(3) 
EtOH,... (mg) 5.84:1:1.71 (3) 7.37:t2.41(3) 
u.._.. = 370 V, -r = 5 ms. contact duration = 2 hours 
p value: calculated using Mann-Whitney test 
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p 
1.00 (NS) 
0.70 (NS) 
0.40 (NS) 
In the passive diffusion study, the amount of CSA delivered into the skin (CSA....) 
and receiver (CSA.....,) did not significantly increase when the contact duration 
was ranging from 2 hours to 12 hours (Table 9 and Figure 11 ). The transport of 
EtOH (EtOH....,) had a significant increase when contact duration increased from 
2 hours to 4 hours. 
In single pulse electroporation study, only the amount of CSA.... was significantly 
inaeased when oontact duration was increased from 2 hours to 4 hours (p < 0.05, 
Mann-Whitney test), while both CSA....., and EtCH,... were not significantly 
different when the contact duration was increased (Table 9 and Figure 12). 
In multiple pulse electroporation study, all the values, CSA..an, CSA..c.., and 
EtOH,..... measured at different contact durations, respectively 2, 4, 6 and 12 
hour, were significantly different according to Kruskal-Wallis test {p < 0. 05). 
However, pair-wise comparison using Mann-Whitney test showed that there were 
significant difference for CSA..an between 2 hours and 4 hours, for CS~ and 
EtOH,... between 4 hours and 6 hours (p = 0.017, after adjusting for Type I 
error). No significant increase in the CSA..an were observed when the different 
contact durations, 4, 6 and 12 hours were applied (p = 0.3104, Kruskai-Wallis test, 
Table 9, Figure 13). 
These results suggest the importance of post-pulse diffusion in the 
eledroporative delivery of CSA. Although it may be difficult to make any definite 
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conclusion from the above observation, it is clear that a study beyond 6-hour 
contact duration is not of any vital advantage. Keeping in mind the therapeutic 
benefit at achieving an optimum CSA..... while maintaining the minimum CSA,_._. 
for the topical treatment of psoriasis and the pradical problems in conduding 
studies for prolonged time periods, a 4-hour contact duration was considered as the 
optimum time period for further studies using multiple electroporative pulse made. 
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Table 9 Effect of Contact Duration of Study on the Delivery of CSA and EtOH 
Duration CSA..,. CSA,..., EtOH...., n 
(hr) x (IJQ) :t SO x (~g) :t SO x (mg) :tSD 
Passive Diffusion 
2 0.25.0.38 0.16 :t 0.17 1 .. 06 :t 0.28 10 
4 0.48 :t 0.29 0.28 :t 0.19 2.08 :t 0 .. 79 11 
6 0.99 :t 1.19 0.86 :t 0.91 5.16:1:2 .. 92 5 
12 0.93 :1: 1.10 1.12 ±0.70 5.22:1:2.96 5 
p(1) 0.073 (NS) 0.042 (Sig) 0 (Sig) 
p(2) NS 0.006 {2-4 hr. Sig) 
Single Pulse (200 V. 1 0 ms) 
2 1.04. 0.41 0.40 :1: 0.23 2 .. 83:1:1.21 5 
i 4 2.90:1: 1.28 0.24 ±0.30 3.10:1:0.98 5 
~ p(l) l 0.022 (Sig) 0.296 (NS) 0.676 (NS) 
i Multiple Pulse (200 v. 10 ms, 25 pulses) 
2 0 .. 87 :t0 .. 39 0.87 ± 0.92 4.81 :1:2.29 5 
4 29.78 :t 20.14 1.03 :t 0.79 6.74:1:1.64 5 
6 55.42 :1: 32.29 3.26 :t 0.72 14.50 :t 2.56 5 
! 12 38 .. 33 :1: 15.23 3.45 :t 0.80 13.85 :t 2.65 5 j. 
~ p(1) 0.007 (Sig) 0.004 (Sig) 0.002 (Sig) ~ 
p(2) 0.012 0.011 0.012 
(Sig 2-4hr} (Sig 4-6hr} (Sig 4-6hr) 
Sig: significantly different, NS: not significantly different 
pC1): p value of Kruskai-Wallis test, p(l): p value of Mann-Whitney test 
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Single Pulse Electroporative Delivery The results of single pulse 
electroporation delivery are summarized in Table 1 0. With our electroporation unit 
there were limitations to the flexibility and control of electrical parameters. It was 
not possible to deliver all pulses at 1 0 ms under all experimental conditions. 
Experimental variables included u.._. 't, and contact duration. Although regional 
skin variation was low in passive diffusion, a relatively high fluduation was found 
in the transdermal delivery by electroporation. Pulsed electromagnetic field tends 
to act on lipoidal multilayers of the SC temporarily breaking it down rNeaver JC, 
1995). Therefore, the regional variation in the lipid composition in SC has an 
important influence in drug delivery during electroporation than that in passive 
diffusion. 
The amount of CSA delivered across the skin into the receiver (CSAr.c...) was 
erratic and no significant difference as the u._. was increased (Table 1 0). In the 
2-hour contact duration study (Figure 14), with the increase in the U...._ from 160 
to 370 V there was a proportional increase in the amount of EtOH....., delivered 
across the skin, except at u ..... = 300 V. It should be noted that due to the lack 
of flexibility and limitations in the our electroporation apparatus, 't = 10 ms could not 
be maintained for all the u..._.. A regression analysis of the EtCH,... delivered 
at 100, 160 and 200 v. 't = 10 ms, yielded a coefficient of determinations, R2 = 97.8 
%. This indicates a linear relationship between EtOH,.._ and IJ1 ... , when 
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u ... < 200 V. As u...,. inaeased, absence of linearity between EtCH,.... and 
u__. could be due to the skin's electrical property which is complicated with the 
subsequent increase in the voltage. This is consistent with studies reported earlier 
by other groups (Kasting GB et al.. 1990; Pliquett U eta/., 1995; Kalia YN et at., 
1995). 
The mean values of CSA..an delivered by electroparation at the different voltages 
appeared to be about 3-4 times higher compared to control in both single and 
multiple pulse electroporation.. However, it was not statistically significant with the 
Mann-Whitney test in pair-wise comparison. 
Theoretical estimates suggest that a minimum transdermal voltage, u .... of about 
100 V is necessary for electroporation effect to occur in human SC (Prausnitz MR, 
1996a). While there are reports of using u.....,. as high as 450 to 1 000 V 
(Vanbever R eta/., 1994; Bommannan DB eta/., 1994) for delivering drugs 
transdermally using eledroporation, we seleded a smaller electrode voltage, viz. 
u._. = 200 V for studying multiple pulse mode to minimize any adverse effed on 
the skin. Although the u .... was not measured, it is expeded to be only a fradion 
of u ..... (Piiquette U eta/., 1995). 
Compared to the control, using single pulse electroporation with 4-hour contad 
duration showed significantly higher values for CSA..r.. and EtOH,...,. (p < 0.05, 
Table 10 and Figure 15). However, inaeasing 'tfrom 5.6 ms to 10 ms did not result 
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in any significant increase in the EtCH...., and the CSA..an delivered (p > 0.05, 
Table 10). 
Before stripping the SC the skin had to be padded using a filter paper. This 
process of drying ccmbined with the volatility of ethanol made it difficult to 
accurately determine EtOHtldft. However. an attempt was made to determine 
EtOH~~~~n during the single pulse electroporation experiments by rapidly working to 
minimize evaporation of ethanol. The results of EtOH~~c~n are given in Table 11. 
Absence of significant difference between the EtCH uptake of the stripped skin 
indicates that the skin has a limited capacity for EtOH uptake and after attaining 
saturation an inaease in the field strength does not make any significant difference 
in EtOH ..... 
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Table 10 Single Pulse Electroporative Delivery of CSA and EtOH 
u.-.... 't Duration CSA..a,. CSA..c..- EtOH...-., 
M (ms) (hr) x (IJQ) :t SO x (IJg) :t SO x (mg) :t SO n 
Control* 2 0.25:1:0.38 0.16 :t 0.17 1.06 ±0.28 10 
100 10 2 0.78:1:0.55 0.26 :t 0.18 1.01 :t 0.82 5 
160 10 2 1.02:1:1.14 0.11 :1: 0.06 1.86 :t 0.49 5 
200 10 2 1.04 :t 0.4i 0.40 :t 0.23 2.83 :1: 1.21 5 
300 7.5 2 0.95 :t0.87 0.21 :t0.23 2.25 :t 1.38 5 
370 5.0 2 0.99 :1: 1.24 0.59 ±0.45 5.53 :t 1.59 5 
Kruskai-Wallis p 0.026 (Sig) 0.053 (NS) 0.001 (Sig) 
·. 
~ 
i Control* 4 0.48 ±0.29 0.28 :t 0.19 2.08 :1:0.79 t 11 
f. 200 5.6 4 2.00 :t 1.40 1.11:1:0.71 4.03 :t 0.67 3 
I 200 10 4 2.90 :t 1.28 0.24 :1: 0.30 3.10 :t 0.98 5 Kruskai-Wallis p 0.002 (Sig) 0.117 (NS) 0.035 (Sig) 
~ 
~ 
• passive diffusion 
I 
~ 
r 
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Table 11 The EtOH Uptake of Skin 
u.....,. Contad Duration EtCH..,. 
(V) (hour) x (mg) :t SO 
100 2 0.36:t0.11 
160 2 0.34:t0.13 
200 2 0.30:t0.20 
300 2 0.28:t0.09 
370 2 0.37:t0.20 
Kruaskai-Wallis p 0.746 (NS) 
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Multiple Pulse Electroporative Delivery at u..._. • 200 V The results of 
multiple pulse electroporative delivery are reported in Table 12. As mentioned 
earlier based on the single pulse electroporation experiments, u.._.. = 200 V was 
selected as the optimum voltage to study multiple pulse electroporation. Compared 
to control the electroporative delivery with multiple pulse at "t= 0.9 ms resulted in 
a significant increase (p < 0.05) only for the delivery of EtCH,...,. Increasing the 
pulse length from 0.9 to 5.8 ms did not result in any significant increase in the 
delivery of any of the quantities. However, further increase in the pulse length to 
1 0 ms led to a significant increase (p = 0.025, after adjusting for Type I error) in 
CSA..., although the other two quantities viz. CSA...- and EtCH,..., did not show 
any significant increase (Figure 16). Among the different analyzed quantities 
CSAr.c..v.r was found to be the least in amount. The amount of CS~ was about 
60 fold higher than in the control with multiple pulse at 4 hour contact duration and 
10 fold compared to single pulse electroporative delivery with the same u.....,.. -r 
and contact duration. With 6 hour and 12 hour contact duration. the increase in 
CSA..., compared to the control, was 40 to 55 times higher (Table 9). The amount 
of EtCH..._ using multiple pulse was only 2-4 times higher than the control. The 
lack of correlation between EtCH....., and CSA...t is difficult to explain. It appears 
that the electroporative force at t = 0.9 ms is sufficient for the transport of the 
relatively small and polar ethanol mol&a.Jies. A further increase in the pulse length 
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without inaeasing thermodynamic activity of ethanol does not increase its transport. 
But far CSA, a large and non-polar molecule, CSA..ctn and CSA...., are dependent 
on the electroporative conditions. Probably due to these differences, there is no 
correlation between EtOH..., and CSA...n as expected. Multiple pulse with longer 
'[ and large U..._. provide higher electroporative force for improved CSA..., A 
recent finding by the Weaver group (Piiquet eta/., 1996 (b)) has reported the 
dependence of the number of localized transport region and size of the pore, on the 
transdermal voltage and number of pulses, respectively. The low values of CSA.... 
with single pulse and a significant inaease with multiple pulse is in agreement with 
these observations. It also appears that there is a threshold value for CSA 
transport and the pulse length of 5.8 ms does not aoss it High lipophilicity (log P oct 
= 2.92) and poor aqueous solubility of CSA seem to be two main factors 
responsible for containing CSA in the skin and minimizing CSA..c.n,.. This however 
could be an advantage in treating psoriasis patients in whom a minimal systemic 
concentration of CSA would reduce the undesirable side effeds. Since there is no 
reported value for the therapeutically required concentration of CSA to treat 
psoriasis topically, we can only make a speculation. Topical delivery (in vitro) of a 
15°4 CSA in an Azone-containing vehicle in human skin is reported to have resulted 
in 78 nglcrn2 in epidermis and 80 nglcni in the dermis (Siren C et al .. 1984). In 
comparison to that we obtained about a 200 fold higher value in the epidermis 
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(stripped of SC) and dennis with multiple pulse mode (25 pulses at u ..... = 200 
V and'[ = 10 ms: CSA.ac.. = 29.78 J.Jg/0.87 cm2). The amount of CSA. can be 
easily reduced, if needed, by adjusting the electroporative conditions. The most 
desirable testimony for the therapeutic efficacy of the electroporative delivery will 
be an in vivo study which will be done in the near future. 
Table 12 Multiple Pulse Electroporative Delivery ofCSA and EtCH 
u ....... = 200 V, Contad Duration: 4 hours, number of Pulses: 25 
"t 
ms 
CSAswn CSA,..,. EtCH..._ n 
x (IJg) ±SO x (IJQ) :t SO x (mg) :t SO 
0.9 2.62 :t 2.47 0.23 :t 0.28 4.09 :t 1.47 4 
5.8 2.09 :t 1.20 1.33 :t 0.80 5.95 :t 1.34 4 
10 29.78 :t 20.14 1.02 :t0.79 6.74 ± 1.64 5 
Kruskai-Wallis 
p 0.014 (Sig) 0.091 (NS) 0.12 (NS) 
Mann-Whitney 
p 0.025 
Sig, 5.8-10 ms 
Sig: significantly different, NS: not significantly different, Level of Sig: 0.05 
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Results of RIA The results of RIA are shown in Table 13. All samples are in 
duplicate and the mean values are reported. The quantitative measuerment of CSA 
was done using a standard curve. in which %8/80 is calculated using following 
formula: 
CPM of standard or samples - CPM of NSB 
%8/80 = x 100 
CPM of 0 standard - CPM of NSB 
The fresh skin seems to interfere with the assay but the measurement of assay is 
lower than that of passive diffusion. Since % cross-reactivity for CSA metabolites 
is less than 2 in the RIA kit, our results have confirmed that electroporation can be 
used to deliver CSA transdermally and the intact CSA exists in the skin samples 
after electroporation and a 4 hour contad duration. However, the results can be 
only taken as a qualitative determination because of interferences and possible 
incomplete extraction of CSA from the skin. The quantity of CSA in the receiver 
sample were similar for passive diffusion and electroporation. This was the same 
with LSC analysis. 
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Table 13 Results of RIA 
Passive Diffusion 
Electroporation 
Passive Diffusion 
Electroporation 
Skin Samples 
Receiver Samples 
6. 7 Effect of Electrical Pulse on the Skin 
0.46 
2.66 
CSA..c.v.r (IJg/0.8 mL) 
0.36 
0.36 
Eledron microscopic photographs show no disruption of the lipid bilayer in the 
SC interstices after pulsing the skin 25 times at u...._ = 200 V and -r = 1 0 ms. The 
outermost layer of SC was noted to have a normal pattem of lamellar sheets, 
similar to untreated skin used as the control (Figure 17 and 18). It is reported that 
high voltage pulsing causes a dramatic increase in the transdermal flux for 
maaomolecules with simultaneous change in the skin's structure. But the structural 
changes in the skin are reversible and also subtle as to be undetedable by electron 
miaoscopy (Prausnitz MR. 1996b ). It is reported that during high voltage pulsing 
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the changes of the skin are on sub-microscopic scale and therefore not expected 
to be detectable by electron miaoscopy {Piiquette U eta/., 1996 (a)). After high-
voltage electroporation, lasting effects in the epidermis are reported in which 
increased transdermal flux generaly persisted for minutes to hours, but the effects 
are reversible (Prausnitz MR eta/., 1994;1995a; Vanbever R eta/., 1994; Pliquett 
U eta/., 1996(a)). In our experiment, we observed that, after single or multiple 
electroporation. transport of water and EtOH across the skin lasted for 24 hours. 
On the other hand, transport of CSA lasted only about +6 hours. This could be due 
to the large molecular size of CSA, which is much larger than those of the solvents. 
This result also suggests that after electroporation the skin is expected to undergo 
a process of recovery. 
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Figure 17 Electron Microscopic Photograph (I) 
Freshly-excised, hydrated skin 
Magnification: 3000 x 2 
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Figure 18 Electron Microscopic Photograph (II) 
Multiple • pulsed skin 
Magnification: 3000 )( 2 
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VII CONCLUSIONS 
Transdermal delivery of CSA would be beneficial in the treatment of psoriasis. 
To deliver CSA transdermally, the electrical means of enhancement seems 
applicable. Although iontophoresis alone is ineffective in enhancing transdermal 
delivery of CSA, electroporation enhances the permeation of the skin to deliver 
CSA. Based on our results, we can make the following conclusions: 
1. Hydroethanolic solution { 40% ethanol in PBS) can be used as a donor 
solution in eledrically enhanced permeation techniques. It has the solvent 
property desirable to dissolve hydrophobic drugs while maintaining the 
eledrical condudivity required fer electroporation experiment. 
2. Preparation of CSA-PVMEJMA copolymer helped in enhancing the aqueous 
solubility of CSA by 10 fold. Electroporative delivery of CSA from 
coevaporate is 4 - 7 times higher than passive diffusion but the amount 
delivered is not significant in comparison with the amount delivered from 
hydroethanolic solution. 
3. By using hydroethanolic donor solution, single pulsed electroporative 
delivery of CSA is significantly higher than the passive diffusion. However, 
use of multiple pulse eledroporation was more effedive than single pulse 
mode in the delivery of CSA into the skin. Multiple pulse electroporative 
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delivery of CSA using hydroethanolic donor solution is about 60 times higher 
than passive diffusion. It is also 1 0 times higher than the single pulse 
electroporative delivery. 
4. The mechanism of enhanced delivery of CSA by electroporation could be 
attributed to the inaease in pore pathway aeated in SC and electro-osmotic 
flux of water and ethanol induced by high voltage electrical pulses. 
5. The contact duration of donor solution is an important factor in the delivery 
of CSA The amount of CSA delivered significantly increased as the contact 
duration was inaeased from 2 hours to 4 hours. However, further increase 
of contact duration from 4 hours to 12 hour did not result in significantly 
different in the delivery of CSA The results suggest that post-pulse diffusion 
is essential to deliver CSA by eledroporation. 
6. From the single pulse electroporation study, parameters of an exponential 
pulse, at u.._ = 200 V and -r = 10 ms, were chosen for the multiple pulse 
electroporation. Further experiments to optimize these conditions for 
multiple pulse electroporation will need to be conducted. 
7. Preliminary electron microscopy study of the skin did not reveal any evidence 
for gross damage of the skin as a result of electroporation. A more detailed 
study using techniques, such as TEWL. and in live animal models to 
evaluate the safety issue of electroporation will have to be performed before 
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trials in humans. 
Now that the in vitro parameters are set satisfadorily the first step in this project 
to achieve a topical delivery of CSA to treat psoriasis has been completed. Further 
work using an animal model should be canied out. 
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